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ABSTRACT 
BACKGROUND AND AIMS: A better understanding of prognostic factors within the 
heterogeneous spectrum of pediatric Crohn’s disease (CD) should improve patient 
management and reduce complications. We aimed to identify evidence-based predictors of 
outcomes with the goal of optimizing individual patient management.  
METHODS: A survey of 202 experts in pediatric CD identified and prioritized adverse outcomes 
to be avoided. A systematic review of the literature with meta-analysis, when possible, was 
performed to identify clinical studies that investigated predictors of these outcomes. Multiple 
national and international face-to-face meetings were held to draft consensus statements 
based on the published evidence.  
RESULTS: Consensus was reached on 27 statements regarding prognostic factors for surgery, 
complications, chronically active pediatric CD, and hospitalization. Prognostic factors for 
surgery included CD diagnosis during adolescence, growth impairment, NOD2/CARD15 
polymorphisms, disease behavior, and positive anti-Saccharomyces cerevisiae antibodies (ASCA) 
status. Isolated colonic disease was associated with fewer surgeries. Older age at presentation, 
small bowel disease, serology (ASCA, antiflagellin, and OmpC), NOD2/CARD15 polymorphisms, 
perianal disease, and ethnicity were risk factors for penetrating (B3) and/or stenotic disease 
(B2). Male sex, young age at onset, small bowel disease, more active disease, and diagnostic 
delay may be associated with growth impairment. Malnutrition and higher disease activity were 
associated with reduced bone density.  
CONCLUSIONS: These evidence-based consensus statements offer insight into predictors of 
poor outcomes in pediatric CD and are valuable when developing treatment algorithms and 
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planning future studies. Targeted longitudinal studies are needed to further characterize 
prognostic factors in pediatric CD and to evaluate the impact of treatment algorithms tailored 
to individual patient risk. 
 
Keywords: ASCA, serology, NOD2/CARD15, growth impairment, polymorphism, prognostic 
factors, structuring or penetrating disease, complications. 
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INTRODUCTION 
Pediatric-onset Crohn’s disease (CD) is heterogeneous. Beyond stricturing (B2), internal 
penetrating (B3) disease and need for surgery, complications in pediatric CD include perianal 
fistulizing disease, linear growth impairment, malnutrition, pubertal delay, and decreased bone 
mineral density (BMD). Early intensified treatment may reduce the development of 
complications
1
 and thus identification of prognostic factors in pediatric CD can improve patient 
management. 
The international pediatric inflammatory bowel disease (PIBD) “Ahead program” (PIBD-
Ahead) aimed to identify evidence-based predictors of poor outcomes in PIBD, with the goal of 
optimally individualizing management based on knowledge of risk factors. The results specific 
to CD are herein reported. 
 
METHODS 
Scope and Purpose 
PIBD-Ahead encompassed several stages, aiming to systematically reach international 
consensus on the predictors of poor outcomes in PIBD. First, a steering committee (SC), 
consisting of two co-chairs (AMG and DT) and 15 members (the other authors), determined 
which undesirable outcomes were most important to predict. Pediatric gastroenterologists 
involved in the care of children with inflammatory bowel disease (IBD) internationally were 
approached through the online PIBD network (https://www.pibd-net.org/) or personal contacts 
to participate in a survey, wherein scale-based questions were used to determine disease 
outcomes, which, if preventable with biologics, would mandate early interventions. 
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Thereafter, a systematic review of the literature was performed to identify studies 
examining predictors of the chosen outcomes. Pooling of the effects between predictors and 
key outcomes was performed using meta-analysis, where possible. Finally, following a series of 
national and international meetings with large groups of PIBD experts, consensus statements 
were formulated based on the evidence. 
Literature Inclusion Criteria 
We considered randomized controlled trials, prospective and retrospective cohort studies, 
and case-control studies that examined pediatric patients (as defined by individual studies) for 
inclusion in the review. Studies that reported on any patient or disease factor as a predictor of 
at least one of the outcomes of interest identified below were eligible. Studies were excluded if 
they were not available in English (for feasibility reasons and given that most major journals 
make articles available in English), or if they were available only in abstract form given that data 
from abstracts and full manuscripts can be inconsistent.  
Systematic Search and Meta-analysis 
In a face-to-face meeting in Prague (May 2017), the scope of the literature review was 
finalized by the SC. Databases searched included Cochrane, EMBASE, and PubMed from January 
1992 to May 2017. Search strings and eligibility criteria were developed specifically for each 
database (see Supplemental Materials). Additional relevant publications were retrieved based 
on review of reference lists of included studies and as suggested during the national meetings 
through discussion with leaders in the field. Bibliographic fellows (MA, AR, EOM, and NC) 
reviewed all abstracts in duplicate to determine which full texts to retrieve. Full texts were also 
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reviewed in duplicate (MA, AR, EOM, and NC). At both stages, disagreements were resolved by 
consensus with input from one of the principal investigators (AMG, DT).   
Data were extracted independently and in duplicate (MA, AR, and EOM) onto standardized 
case report forms. Extracted data included the following: study characteristics (design, 
single/multicenter, number of participants); participant characteristics (IBD type, age, sex); 
outcome(s) and predictor(s) examined (including definitions); and follow-up duration/timing of 
outcome assessment. For studies included in meta-analyses, effect estimates, expressed either 
as 2x2 tables (number of participants with and without the predictor who experienced the 
outcome), odds ratio (OR) and/or hazard ratio (HR), were extracted as well as whether results 
were unadjusted or adjusted. Otherwise, studies were reviewed qualitatively for whether they 
demonstrated a significant association between a predictor and outcome. Study authors were 
not contacted for missing data given the large number of included studies. 
Risk of bias was assessed for all studies by a single rater (MA, AR, EOM) using the 
Newcastle-Ottawa Scale, as appropriate for observational studies (no randomized controlled 
trials were identified). The Newcastle-Ottawa Scale is based on eight factors (total score range 
0–9) across three domains, namely selection, comparability, and outcome/exposure. We 
defined a high-quality study as a total score of 8–9, moderate quality as 5–7, and low quality as 
0–4.  
We decided a priori that we would attempt to meta-analyze only the most clinically 
pertinent and homogeneous outcomes, which, by consensus, we identified to be surgery and 
B2/B3 complications. Studies examining these outcomes were not pooled if they were felt to be 
too clinically heterogeneous. For dichotomous outcomes, the pooled measure of treatment 
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effect was OR and, for time to event outcomes, the pooled measure of treatment effect was HR, 
both expressed with 95% confidence intervals (CI). Results were pooled using random effects in 
all cases, as we expected at least some clinical heterogeneity between studies. This was 
accomplished using inverse variance and DerSimonian and Laird methods. Statistical 
heterogeneity was evaluated across pooled studies using the I
2
 statistic. Heterogeneity was also 
explored graphically by examining outliers in forest plots. ORs and HRs were considered 
separately and, where both were available, both were presented. Univariate and multivariable 
effect estimates were also generally considered separately. However, univariate and 
multivariable effect estimates were pooled if point estimates were similar (provided that 
adjustment did not substantially alter the association between predictor and outcome) or 
statistical heterogeneity was low (I
2
 ≤40%).
2
 We had planned to assess publication bias 
graphically using funnel plots, but this was not possible due to insufficient study numbers (<10) 
per outcome. Analyses were performed using R version 4.0.0. 
Consensus Process 
The consolidated report and draft statements were reviewed by the SC, and the validity of 
the statements was discussed at national face-to-face meetings organized by AbbVie in 27 
countries, including Argentina, Australia, Austria, Bahrain, Belgium, Canada, Czech Republic, 
Denmark, France, Germany, Greece, Hungary, Ireland, Israel, Italy, the Netherlands, Qatar, 
Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, and the 
United Kingdom. Comments received during the meetings were considered by the SC during a 
second face-to-face meeting of the SC in September 2017 in Barcelona, where the statements 
were finalized. 
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At the final February 2018 consensus meeting in Vienna, the SC and national 
representatives (53 participants) voted on the statements. A statement was accepted if ≥80% of 
participants voted 4 (agree) or 5 (strongly agree) on a scale of 1–5 (with 1, 2, and 3 indicating 
strongly disagree, disagree, and uncertain, respectively). Statements not achieving agreement 
were further revised and subjected to repeat vote until consensus was reached for all 
statements. In general, soft wording, such as “may predict”, has been used when only one 
positive study was available or when there was more than one positive study, but also with 
negative conflicting studies.  
 
RESULTS 
The international survey of outcome selection was completed by 202 practicing 
pediatric gastroenterologists from 33 countries. Based on the survey, the SC concluded that the 
most important undesirable outcomes to predict in CD could be categorized as disease 
complications (including B2 and B3 disease), intestinal resection, perianal fistulizing disease, 
chronically active inflammatory disease, significant growth impairment, and bone disease. B2 
and B3 complications and intestinal resection were selected for meta-analysis.  
The results of the search are presented in the PRISMA diagram in Supplemental Figure 1. 
One hundred and one studies were included, of which 42 were included in the quantitative 
meta-analysis. Study characteristics and risk of bias for studies examining predictor-outcome 
combinations included in meta-analyses are shown in Table 1 and Table 2, respectively. The 
equivalent data for studies examining predictor-outcome combinations not included in meta-
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analyses are shown in Supplemental Tables 1 and 2. All included studies were observational. 
Thirty-one studies were high quality, 45 moderate quality, and 25 low quality. 
Figure 1 tabulates the final consensus statements. Table 3 presents the extracted 
numeric data for predictor-outcome pairs included in meta-analyses. Table 4 presents an 
intuitive summary of each outcome. A summary of the most pertinent literature is provided 
below each statement (for a full review of each predictor, see Supplemental Materials). 
 
Prognostic Factors for Surgery 
Statement 1.1. Diagnosis in adolescence (>13 years of age), compared with younger age, may 
predict increased risk of bowel surgery within 5 years of diagnosis (94% agreement). 
Thirteen studies
3-15
 assessed age as a possible predictor of bowel surgery; of these four 
found older age (>13 years) to be a significant predictor of surgery.
4-7
 The largest cohort with 
significant findings included 989 children aged 0–17 years and found an adjusted OR of 1.12 per 
1-year increase in age (95% CI 1.06–1.18, P<.0001).
6
 
 
Statement 1.2. Growth impairment at diagnosis predicts increased risk of bowel surgery (81% 
agreement). 
Five studies evaluated the association of growth impairment with the risk of bowel 
surgery, of which three showed a significant association.
4, 6, 8, 14, 16
 Two meta-analyzable studies 
revealed a 1.72-fold higher risk for surgery in patients with growth impairment (pooled HR 1.72, 
95% CI 1.27–2.33, P=.0004, n=1,438, I
2
=0%, Figure 2A).
6, 16
 One of the two negative studies had 
a mixed PIBD cohort rather than CD only.
14
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Statement 1.3. Disease location may predict surgery; isolated colonic disease is associated 
with fewer surgeries (84% agreement). 
Twelve studies evaluated disease location as a predictor for the risk of surgery.
4-10, 16-20
 
Four meta-analyzable studies showed a significantly lower risk of surgery in patients with 
isolated colonic disease (pooled HR 0.57, 95% CI 0.43–0.78, P=.0003, n=2,289, I
2
=24%, Figure 
2B).
5, 6, 10, 16
 The pooled unadjusted OR from a smaller analysis of two studies with no 
heterogeneity further supported this (pooled OR 0.30, 95% CI 0.15–0.58, P=.0003, n=621, I
2
=0%, 
Supplemental Figure 2A).
16, 17
 Conversely, this indicates that the presence of small bowel 
disease (isolated or with colonic disease) increases the risk of surgery. Of the studies that could 
not be included in the meta-analysis, three reported disease location to not be a significant risk 
factor.
7-9
 Attard et al. found jejunal involvement and disease in the proximal ileum to be 
associated with an increased surgery risk (unadjusted HR 3.7, P<.03), but upper gastrointestinal 
(GI) disease and esophageal involvement were not found to be significant risk factors by two 
other studies.
4, 20
  
 
Statement 1.4. Inconclusive evidence exists for sex as a predictor for surgery; presence of 
NOD2/CARD15 variants, stricturing and/or internal penetrating (B2/B3) phenotype, and 
positive anti-Saccharomyces cerevisiae antibodies (ASCA) status predict surgery; ethnicity and 
presence of granulomas at diagnosis do not predict surgery (90% agreement). 
Ten studies 
5, 6, 9-12, 14, 16, 17, 21
 evaluated the association between sex and surgery. Meta-
analysis of six studies
5, 6, 9, 11, 16, 17
 found no significant risk for sex (pooled OR 0.95, 95% CI 0.73–
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1.22, P=.27, n=2,780, I
2
=22%, Figure 2C). A smaller analysis of five studies with greater 
heterogeneity showed a decreased risk of surgery with male sex but bordered the null (pooled 
HR 0.82, 95% CI 0.68–0.99, P=.04, n=4,256, I
2
=36%, Supplemental Figure 2B).
6, 10, 12, 16, 21
 The 
largest study, not included in the meta-analysis, reported male sex to be a significant risk factor 
in a mixed IBD cohort.
14
 Conversely, Dubinsky et al., also not included in the meta-analysis, 
reported an increased risk for females in a multivariable analysis (HR 1.69, 95% CI 1.07–2.17, 
P<.009). The two remaining studies did not report a significantly increased risk for either sex.
10, 
12
 
Eleven studies evaluated the presence of a NOD2/CARD15 variant as a predictor of 
surgery,
18, 21-30
 of which three found a significant association.
26-28
 The largest cohort of 186 
patients with childhood-onset CD found a higher risk for surgery in those with a 3020insC 
mutation (adjusted HR [aHR] 5.83, 95% CI 2.62–12.98, P<.0001).
27
 The data from six studies 
could be pooled, which resulted in a 2-fold increased risk (pooled OR 2.02, 95% CI 1.23–3.32, 
P=.006, n=797, I
2
=35%, Figure 2D).
22-26, 28
 
Disease behavior was evaluated as a risk factor for surgery in four studies.
5, 8, 10, 16
 
Pooled HR of 2.55 for B3 disease behavior (95% CI 0.95–6.88, P=.06, n=1,248, I
2
=46.0%, Figure 
2E)
5, 10
 and a pooled HR of 3.97 (95% CI 1.56–10.10, P=.004, n=1,248, I
2
=81.1%, Figure 2F) for B2 
disease behavior was found.
5, 10
 Rinawi et al. found children with B2/B3 disease to be at 
increased risk of surgery (aHR 2.54, 95% CI 1.59–4.05, P<.001).
16
 
Five
6, 16, 17, 21, 31
 out of eight studies
6, 16, 17, 21, 31-34
 evaluating the association between 
ASCA status and surgery showed a significant association. The pooled OR for five meta-
analyzable studies was 2.31 (95% CI 1.74–3.06, P<.0001, n=1128, I
2
=0, Figure 2G).
16, 17, 21, 31, 32
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The pooled HR for four of these studies also demonstrated a significantly increased risk of 
surgery (HR 2.59, 95% CI 1.63–4.11, P<.0001, n=1033, I
2
=0%, Supplemental Figure 2C).
6, 16, 17, 21
 
Of the three studies without a significant association,
32-34
 one included both CD and ulcerative 
colitis (UC).
33
 Ethnicity did not predict the risk of surgery.
5, 6, 9, 35
 Presence of granulomas was 
not associated with the risk of surgery.
6, 16, 36-38
 
 
Prognostic Risk Factors for Complications in Pediatric CD 
Statement 2.1. Children who develop CD at an older age may be at increased risk of 
developing internal penetrating (B3) complications, but not stricturing (B2) disease (94% 
agreement). 
Three studies
18, 39, 40
 found no association between age and progression to B2 disease, 
none of which could be meta-analyzed due to differing methods (univariate vs multivariable 
Cox regression) and age definitions. Two
39, 40
 of four studies,
14, 18, 39, 40
 including the RISK study,
40
 
a large (n=913) prospective inception cohort of pediatric CD, found an association between 
older age during childhood and increased risk of B3 complications. The RISK study was the only 
prospective and high-quality study among the four. No association was reported between age 
and progression to the combined outcome of B2 or B3 complications in four studies.
41-44
 Meta-
analysis was not possible due to differences in age definitions and differences in the effect 
estimates used in individual studies. 
 
Statement 2.2. CD patients of Black ethnicity/race are more likely than White patients to 
develop penetrating (B3) disease (82% agreement). 
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When pooled, two studies, including the RISK cohort, found non-White children to be at 
higher risk of progressing to penetrating complications than White children (pooled OR 3.46, 95% 
CI 1.67–7.17, P=.0009, n=1,020, I
2
=0%, Figure 3A).
40, 45
 The RISK study compared Black children 
to White children in a large cohort and adjusted analysis (HR 3.19, 95% CI 1.39-7.31). By 
comparison, the study by Li et al. examined a small South Asian cohort (n=13) in an unadjusted 
analysis and did not find a significant association (OR 2.05, 95% CI 0.49-8.53). In a third study 
including 105 children with inflammatory CD, Black children progressed more rapidly to the 
combined outcome of B2 or B3 complications (OR 3.48, 95% CI 1.32–9.17, P=.011, n=137).
35
 In 
these studies, follow-up duration ranged from 3 to 10 years. 
 
Statement 2.3. CD patients with small bowel disease (ie, L1 or L3 +/– L4b) have an increased 
risk of developing stricturing complications (B2) and may be at an increased risk of developing 
penetrating complications (B3) (85% agreement). 
 Three studies examined the association between disease location and stricturing 
complications. Although the RISK study found no association in adjusted analyses for isolated 
ileal disease (aHR 1.60, 95% CI 0.88–2.91, P=.12),
40
 when unadjusted results for any small bowel 
involvement from this study were pooled with a second study,
46
 any small bowel disease was a 
significant risk factor for B2 behavior (pooled OR 1.93, 95% CI 1.22–3.05, P=.005, n=1,513, 
I
2
=6%, Figure 3B). A smaller (n=36) uncontrolled study found no such association.
11
 Four studies 
reported on disease location and the combined outcome of B2 or B3 complications; three could 
be meta-analyzed,
43, 44, 46
 revealing an increased risk with ileal involvement (isolated ileal or 
ileocolonic) compared to isolated colonic disease (pooled OR 2.16, 95% CI 1.26–3.71, P=.005, 
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n=819, I
2
=36%, Figure 3C). The fourth study, which could not be meta-analyzed, was 
retrospective and reported B2/B3 as a composite outcome that also included anti-tumor 
necrosis factor (TNF) use (HR 1.38, 95% CI 0.63–3.03, P=.44).
42
 Neither of the two studies to 
examine disease location and B3 complications found a significant association.
40, 46
 They could 
not be meta-analyzed. 
 
Statement 2.4.1. Antimicrobial serologies predict progression to stricturing (B2) and/or 
internal penetrating (B3) complications: ASCA positivity predicts progression to internal 
penetrating (B3) complications and may predict progression to stricturing (B2) complications; 
a higher ASCA immunoglobulin (Ig) A titer predicts progression to penetrating (B3) 
complications (94% agreement). 
The literature on antimicrobial serology and progression to complicated CD in children is 
difficult to interpret, given the heterogeneity of tests investigated. Overall, it appears that an 
association exists, particularly between ASCA positivity and B3 disease. The RISK study 
identified a trend toward an association between ASCA-IgA and B2 disease in an adjusted 
survival analysis (aHR 1.69, 95% CI 0.94–3.07).
40
 A much smaller and unadjusted analysis 
identified no association between ASCA positivity and early B2 complications.
11
 Furthermore, 
the RISK study identified a clearly increased risk of B3 complications with ASCA-IgA positivity 
(aHR 2.68, 95% CI 1.19–6.04), which remained similar in magnitude when pooled with another 
adjusted study (pooled HR 2.75, 95% CI 1.53–4.97, P=.0008, n=1,052, I
2
=0%, Figure 3D).
17, 40
 The 
pooled unadjusted OR for these two studies was 4.45 (95% CI 2.43–8.16, P<.0001, I
2
=0%, 
Supplemental Figure 2D). A large adjusted study also demonstrated an association between 
Jo
urn
a  
Pr
e-p
roo
f
18 
 
ASCA-IgA titer and B3 disease (HR 1.20, 95% CI 1.08–1.34, P=.0009, n=139).
17
 The one study 
that did not support an association between ASCA-IgA (positivity or titer) and B3 disease was 
substantially smaller and did not employ survival analysis.
34
 On the other hand, for ASCA-IgG 
positivity, two studies found no association with B3 disease (pooled OR 1.58, 95% CI 0.75–3.36, 
P=.231, n=200, I
2
=2.7%, Figure 3E).
17, 34
 Both studies were individually negative when examining 
ASCA-IgG titer as well.  
 
Statement 2.4.2. Antiflagellin (CBir1) positivity predicts progression to stricturing (B2) and/or 
internal penetrating (B3) complications; OmpC positivity may predict progression to 
stricturing (B2) and/or internal penetrating (B3) complications (94% agreement). 
The RISK study observed a strong association between CBir1 positivity and B2 as well as 
B3 complications.
40
 Similarly, in a longitudinal cohort of 536 children, CBir1 and, separately, 
OmpC positivity, both predicted B2 or B3 complications over time.
21
 
 
Statement 2.4.3. Seropositivity for ≥1 microbial serologies predicts progression to stricturing 
(B2) and/or internal penetrating (B3) disease; a higher number of positive serologies and 
higher titers may confer a greater risk (94% agreement). 
The pooled results from two studies support an increased risk of developing B2 or B3 
complications with any antimicrobial seropositivity (eg, ASCA, anti-OmpC, or anti-CBir1) 
compared with negative status for all serologies (pooled OR 3.20, 95% CI 1.41–7.26, P=.0055, 
n=703, I
2
=0%, Figure 3F).
21, 47
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Statement 2.5. Polymorphisms in the NOD2/CARD15 gene predict ileal disease location and 
may predict stricturing (B2) disease, but location is inadequately controlled for (90% 
agreement). 
Twelve studies explored the association between NOD2 and B2 complications, including 
nine that could be meta-analyzed, which showed an increased risk of B2 disease (pooled OR 
3.10, 95% CI 1.70–5.65, P=.0002, n=1,050, I
2
=55%, Figure 3G).
18, 23-29, 48
 The three studies that 
could not be pooled found no association.
40, 49, 50
 Since most of these studies did not adjust for 
disease location, it is unclear whether NOD2’s association with B2 disease stems directly from 
its association with ileal location. A meta-analysis of nine of the 11 studies that assessed the 
association between NOD2 and B3 complications revealed no increased risk (pooled OR 1.48, 
95% CI 0.78–2.81, P=.23, n=1,050, I
2
=48%, Figure 3H).
18, 23-29, 48
 The two additional studies that 
could not be meta-analyzed were also negative.
40, 50
 
 
Statement 2.6. The presence of perianal disease may predict stricturing (B2) and/or internal 
penetrating (B3) complications (89% agreement). 
Two studies yielded conflicting findings on perianal disease as a predictor of B2 or B3 
complications.
44, 51
 When pooled, although the effect estimate was in the direction of an 
increased risk of B2/B3 disease in children with perianal disease, this did not achieve statistical 
significance (pooled OR 1.98, 95% CI 0.51–7.74, P=.32, n=383, I
2
=80%, Figure 3I). Notably, there 
was substantial heterogeneity in this analysis. An administrative database study reported an 
increased risk of internal fistulae (rectourethral, rectovaginal, or enterovesical) in the setting of 
perianal disease (OR 3.50, 95% CI 1.98–6.20, n=12,465); although, in the same study, perianal 
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disease was associated with a decreased risk of entero-enteric fistulae (OR 0.30, 95% CI 0.15–
0.63).
14
  
 
Statement 2.7. Sex, family history of IBD, disease activity at baseline, granulomas, upper GI 
tract involvement, presence of extraintestinal manifestations, and diagnostic delay do not 
predict disease location, stricturing (B2) and/or internal penetrating (B3) complications (83% 
agreement). 
Sex was not found to predict B2/B3 complications in seven of eight studies examining 
this association.
11, 41-44, 52, 53
 Similarly, family history of IBD (0/3 studies positive),
11, 42, 44
 baseline 
clinical and biochemical disease activity (one study positive,
43
 five negative),
11, 41, 42, 44
 
granulomas (0/6 studies positive),
36-38, 41, 44, 54
 extraintestinal manifestations (0/2 studies 
positive),
42, 44
 diagnostic delay (0/1 study positive),
44
 and upper GI tract involvement (0/3 
studies positive)
41-43
 were not associated with progression to complicated CD. 
 
Statement 2.8. Older age at CD onset may be associated with an increased risk of developing 
perianal disease (97% agreement). 
The oldest age group (17–21 years of age) at disease onset of 7,076 patients in the 
ImproveCareNow Network had a higher rate of perianal disease than younger children (HR 
1.13, 95% CI 1.10–1.15).
55
 In a second study, including 215 children, older age at diagnosis was 
also associated with more perianal disease over time.
44
 Furthermore, Gupta et al. observed a 
trend toward more perianal disease in children >5 years of age (vs younger children).
39
 In 
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contrast, children with and without perianal disease did not differ in terms of age in the RISK 
study.
40
 
 
Statement 2.9. Children and adolescents of Black and South Asian ethnicity with CD are at a 
greater risk of developing perianal disease (92% agreement). 
Black
55
 (adjusted OR 2.47, P=.017) and South Asian
45
 children were at higher risk of 
developing perianal disease than Caucasian children. 
 
Statement 2.10. Bacterial serology and sex may be associated with the development of 
perianal disease; genetics, antineutrophil cytoplasmic antibody (ANCA) positivity, 
anthropometric parameters, disease location, disease behavior, extraintestinal 
manifestations, diagnostic delay, and disease activity do not predict the development of 
perianal disease (86% agreement). 
ASCA, antilaminaribioside carbohydrate antibodies, antimannobioside carbohydrate 
antibodies, and anti-L antibodies were associated with the composite outcome of perianal 
disease or B2/B3 complications in one study.
32
 In the RISK cohort, children with perianal disease 
at diagnosis were more likely to be ASCA IgA/IgG, CBir1, GM-CSF, and OmpC-positive, and the 
proportion of males was greater among children with perianal disease.
40
 However, both these 
studies examined perianal disease in a cross-sectional manner. Only one
55
 of three
44, 53
 
additional studies found an association between sex and risk of perianal disease. Two of these 
additional studies
44, 55
 examined the development of perianal disease over time, while the other 
was cross-sectional in nature.
53
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Overall, genetics (two studies positive,
56, 57
 nine negative, including for NOD2),
22, 23, 27-29, 49, 50, 
58, 59
 ANCA positivity (0/2 studies positive),
40, 60
 anthropometric parameters (0/3 studies 
positive),
44, 55, 61
 disease location (0/3 studies positive),
40, 44, 55
 disease behavior (0/1 study 
positive),
44
 extraintestinal manifestations (0/1 study positive),
44
 diagnostic delay (0/1 study 
positive),
44
 and disease activity (0/3 studies positive)
40, 44, 55
 did not predict the development of 
perianal disease over time. 
 
Statement 2.11. Male sex, younger age at disease onset, and isolated small bowel disease 
may be associated with a greater risk of linear growth impairment (100% agreement). 
Although five studies found no association between sex and growth,
4, 62-65
 four other 
large and well-designed studies did observe males to be at higher risk of linear growth 
impairment.
53
 
66
 
67, 68
 The studies on age in relation to growth impairment are conflicting. Four 
found no association,
39, 53, 63, 68
 though two were mixed IBD studies.
63, 68
 In four additional 
studies, younger age at diagnosis predicted growth impairment,
4, 62, 65, 67
 and a single study 
observed the opposite.
69
 These differences may relate to varying definitions for growth 
impairment as well as failure to adjust for pubertal status. Three growth-focused studies found 
small bowel disease (vs colonic location) to be associated with growth impairment,
65, 66, 70
 
whereas five others of poorer quality did not report this association.
4, 8, 62, 63, 71
 
 
Statement 2.12. More active disease (assessed at baseline or over time) predicts linear 
growth impairment (92% agreement). 
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Some studies supported an association between more active disease and poorer 
growth, though most were cross-sectional rather than truly predictive. Specifically, two studies 
observed an association between more severe clinical disease and impaired growth,
63, 70
 
whereas two did not.
8, 62
 Four studies found an association between higher erythrocyte 
sedimentation rate and growth impairment,
68, 69, 72, 73
 whereas three found no association 
between C-reactive protein or albumin and linear growth.
63, 69, 72
 
 
Statement 2.13. Diagnostic delay is a risk factor for linear growth impairment (92% 
agreement). 
Two studies focused on CD found an association between diagnostic delay and impaired 
growth.
66, 74
 Two studies that did not differentiate between CD and UC found no such 
association.
68, 75
 
 
Statement 2.14. NOD2/CARD15 polymorphisms may be associated with low weight, and 
extraintestinal manifestations may be associated with linear growth impairment; pubertal 
status at disease onset, family history of IBD, ethnicity, gestational age, upper GI tract 
involvement, oral involvement, granulomas, disease behavior, perianal disease, and 
presenting symptoms do not predict linear growth impairment (94% agreement). 
Three studies examined NOD2/CARD15 in relation to growth,
26, 29, 70
 only one of which 
was positive, reporting that 50% of children with at least one NOD2/CARD15 variant were in the 
lowest weight percentile (<4%) compared with 16% of children without a variant.
26
 One study 
observed an association between extraintestinal manifestations and lower height at last follow-
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up,
67
 whereas another found no such association in a mixed IBD cohort.
68
 Pubertal status at CD 
diagnosis (0/2 studies positive),
62, 71
 family history of IBD (0/3 studies positive),
8, 62, 68
 ethnicity 
(0/3 studies positive),
35, 62, 68
 gestational age (0/1 study positive),
8
 presence of granuloma (0/1 
study positive),
38
 perianal disease (0/2 studies positive),
4, 76
 disease behavior (0/2 studies 
positive),
8, 62
 specific IBD symptoms (0/1 study positive),
53
 upper GI tract location (0/6 studies 
positive),
4, 62, 63, 67, 70, 77
 and oral involvement (0/1 study positive)
78
 were not associated with 
growth impairment. 
 
Statement 2.15. Low height, weight, and body mass index predict reduced BMD (98% 
agreement). 
All 10 studies that examined nutritional status/anthropometrics in relation to reduced 
BMD reported an association with either lower weight or lower height.
29, 79-87
 For weight, 9/9 
studies were positive,
29, 79-85, 87
 and for height, 5/8 studies were positive,
79, 80, 83, 85, 88
 while three 
were negative.
29, 81, 87
 Importantly, most studies reporting on height were cross-sectional. 
 
Statement 2.16. Higher clinical disease activity (assessed by Pediatric CD Activity Index 
[PCDAI]) at baseline and over time may predict reduced BMD (98% agreement). 
Ten studies investigated disease activity in relation to bone outcomes, with 
heterogeneous results, possibly since several were cross-sectional.
29, 79, 81-83, 85, 87, 89-91
 Five 
studies found an association between clinical disease activity and BMD,
82, 89
 
29, 81, 85
 whereas five 
other studies did not,
79, 83, 87, 90, 91
 including two prospective studies.
87, 90
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Statement 2.17. Sex, disease location, disease behavior, extraintestinal manifestations, 
granulomas, and perianal disease do not predict BMD (84% agreement). 
No association has been shown between sex and bone health in seven pediatric 
studies,
29, 53, 79, 80, 83, 85, 92
 while two showed contradictory associations.
88, 89
 Disease location (0/3 
studies positive),
29, 83, 87
 behavior (0/1 study positive),
29
 extraintestinal manifestations (0/2 
studies positive),
29, 85
 presence of granuloma (0/1 study positive),
83
 and perianal disease (0/1 
study positive)
85
 were not predictive of bone outcomes. 
 
Prognostic Risk Factors for Chronically Active Inflammatory Pediatric CD 
Statement 3.1. ASCA positivity may predict the need for more intensive therapy (89% 
agreement). 
Three studies examined ASCA positivity as a predictor for intensified therapy,
11, 33, 93
 two 
of which identified a positive association.
33, 93
 
 
Statement 3.2. Microscopic ileocolonic involvement at diagnosis may be associated with 
subsequent macroscopic ileocolonic disease (98% agreement). 
One study of 212 children reported on microscopic ileocolonic involvement as an 
independent predictor of the subsequent development of macroscopic disease.
44
 The need for 
an immunomodulator or anti-TNF within the first year, and number of flares and 
hospitalizations were associated with disease-extent progression, but only microscopic 
ileocolonic involvement remained significant in the multivariable analysis (HR 4.32, 95% CI 
1.93–9.67). 
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Statement 3.3. Disease activity and disease behavior (ie, B2 and/or B3), but not age and sex, 
may predict more intensive therapies or a poor response to therapies; there is no strong 
evidence for a predictive value of ethnicity (83% agreement). 
Three studies examined the association between PCDAI at diagnosis and subsequent 
treatment,
94-96
 of which only one (n=240) reported an association with the need for 
immunomodulators by 1 year.
96
 One of two studies found an association between B3 behavior 
and use of anti-TNF.
57, 95
  
Only 2/10 studies reported an association between age and intensified treatment.
3, 11, 13, 39, 
64, 97-101
 The first, a prospective registry of 1,928 children, found that younger children (1–5 
years) received corticosteroids and methotrexate more often than older children, but with a 
similar rate for biologics.
100
 The other study found that younger children (0–5 years) received 
steroids more often but with a similar rate for immunomodulators or biologics.
3
 
Sex was not found to predict intensified therapy in four studies.
64, 97, 99, 101
 One study 
reported an association between male sex and better response to steroids, but this was not 
maintained over time.
97
 
Two studies evaluated ethnicity and intensified therapy. Although positive, they did not 
separate CD from UC patients, and each assessed different ethnicities (South Asian
45
 or Black
35
 
vs White). 
 
Statement 3.4. No strong evidence exists to identify predictive factors of future disease 
activity or disease severity (81% agreement). 
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Of three studies investigating predictive factors of disease severity in pediatric CD,
8, 60, 65
 
two identified an association.
8, 65
 The first study found an association between ileal/ileocolonic 
location and PCDAI or Physician Global Assessment.
8
 In the second, the presence of 
TNF 308G/A genetic polymorphism was associated with a trend for severe disease, as 
represented by hospitalizations, surgery, and need of steroids or anti-TNF.
65
 No association was 
found between ANCA serology and disease course.
60
 
 
Statement 3.5. No strong evidence exists for predictors of disease relapse and the number of 
relapses (98% agreement). 
Four
13, 23, 34, 102
 of six
77, 78
 studies reported significant predictors for disease relapse (as 
defined by clinical activity score), including ASCA IgA positivity,
34
 younger age at disease 
onset,
13
 ATG16L1 risk allele homozygosity,
23
 and a polymorphonuclear neutrophil CD64 
index >1.0 (vs <1.0).
102
 Gasparetto et al. found children aged 5–10 years at diagnosis to relapse 
more frequently than children with disease onset at 11–16 years of age (mean relapse per 
patient per year 1.4 ± 0.2 standard deviation [SD] vs 0.85 ± 0.1 SD, respectively; OR 1.2, 95% CI 
1.01–1.65). However, owing to study limitations of sample size, retrospective design, and 
heterogeneity in the results, these findings do not represent strong evidence for predictors of 
occurrence or number of disease relapses. 
 
Statement 3.6. Stricturing and/or internal penetrating (B2/B3) phenotype and the presence 
of granulomas and increased visceral adipose tissue may predict hospitalizations; small bowel 
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involvement, TNF polymorphisms, NOD2 variants, and age do not predict hospitalization (88% 
agreement). 
Predictors for hospitalizations were investigated in seven studies, all with different 
predictors.
13, 19, 29, 37, 65, 100, 103
 Age,
13, 100
 proximal bowel involvement,
19
 and the presence of 
NOD2 variants
29
 or TNF polymorphisms
65
 were not associated with hospitalization. One study 
found that patients with granulomas were more likely to be hospitalized (HR 1.43, 95% CI 1.0–
2.0), whereas they did not display an increased risk for bowel resections or flares.
37
 Uko et al. 
found increased visceral adipose tissue to be associated with hospitalizations (OR 1.9, 95% CI 
1.2–3.4, P=.01) in a retrospective study.
103
 Although no studies evaluated the association 
between B2/B3 disease and hospitalization, the association of B2/B3 disease with surgery as 
mentioned in statement 1.4 reflects this association. This was supported by a recent study 
showing that B2/B3 disease was associated with an increased risk for hospitalization (HR 1.5, 95% 
CI 1.1–2.1, P=.016).
104
 
 
IMPLICATIONS FOR PRACTICE 
The concept of severe CD in children is recognized to encompass not only progression to 
intestinal complications requiring extensive or repeated resection, but also chronically active 
disabling disease, which remains inflammatory. This may lead to other age-specific outcomes 
such as growth impairment and reduced bone density, which can further adversely impact 
children emotionally during a particularly sensitive time in their adolescence. Physicians 
intuitively risk-stratify patients soon after diagnosis and make treatment recommendations 
aiming to prevent these undesirable outcomes. However, evidence-based tools to stratify 
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patient risk and tailor treatment selection accordingly are needed. This is particularly salient as 
there is good evidence of better outcomes resulting from earlier effective medical intervention 
in pediatric CD. This was shown in the RISK cohort, for example, in which early anti-TNFα 
treatment within 3 months of diagnosis was associated with improved clinical and growth 
outcomes at 1 year.
1
  
This project represents the most comprehensive review of the available literature to this 
date in an attempt to develop evidence-based guidance on risk factors for severe pediatric CD. 
As such, it represents an important and contemporary addition to the literature. The 
involvement of a large number of pediatric IBD experts from around the world and the 
consensus approach are important strengths of this undertaking. There are, however, a number 
of limitations. Firstly, despite the comprehensive search strategy, there was a paucity of large, 
prospective, pediatric-specific CD studies for several of the predictor-outcome pairs. Meta-
analyses, in general, included a fairly small number of studies. In some cases, studies pooled CD 
and UC populations. This highlights the need for additional large and rigorously performed 
longitudinal studies in pediatric CD, both to further characterize prognostic factors and to 
evaluate the benefits of treatment algorithms that tailor treatment based on risk stratification 
informed by these risk factors. Additional limitations include heterogeneity of included studies. 
Sources of heterogeneity included definitions of predictors and outcomes, with growth being 
one example of a factor for which various definitions were used, as well as differences in the 
types of effect measures reported by individual studies. While we made efforts to pool studies 
when justified based on similar definitions and types of effect measures, substantial 
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heterogeneity remained for some analyses. In addition, we excluded non-English texts and 
were unable to contact study authors.  
In summary, the present consensus statements offer clinicians evidence of associations 
between baseline characteristics and outcomes in children with CD. Antimicrobial antibodies 
may be associated with stricturing or internal penetrating CD and surgery, but biomarkers of 
equally disabling chronic inflammatory colonic disease or progressive perianal fistulizing disease 
are direly needed. As in adults, precision medicine is not yet a reality in pediatric CD. 
Nonetheless, the associations summarized and meta-analyzed through PIBD-Ahead provide 
some guidance to the physician making initial treatment decisions for the individual child. 
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Figure Legends 
 
Figure 1. Summary of Consensus Recommendations for the Management of Inflammatory 
Disease 
 
Figure 2. Forest plots for predictors of surgery in pediatric CD: A – poor growth; B – isolated 
colonic disease; C – male sex; D – NOD2/CARD15 variant; E – B3 behavior; F – B2 behavior; G – 
ASCA positivity 
 
Figure 3. Forest plots for predictors of B2/B3 complications in pediatric CD: A – non-White 
ethnicity/race as a predictor of B3 complications; B – small bowel disease (±colonic) as a 
predictor of B2 complications; C – small bowel disease (±colonic) as a predictor of B2 or B3 
complications; D – ASCA-IgA positivity as a predictor of B3 complications; E – ASCA-IgG 
positivity as a predictor of B3 complications; F – antimicrobial seropositivity as a predictor of B2 
or B3 complications; G – NOD2 polymorphisms as a predictor of B2 complications; H – NOD2 
polymorphisms as a predictor of B3 complications; I – perianal disease as a predictor of B2 or 
B3 complications 
 
Table Legends 
 
Table 1. Characteristics of Studies Examining Predictor-Outcome Combinations Included in 
Meta-Analysis 
 
Table 2. Risk of Bias for Studies Examining Outcomes Included in Meta-Analysis 
 
Table 3. Findings from Individual Studies Examining Predictor-Outcome Combinations Included 
in Meta-Analysis 
 
Table 4. Summary of Outcomes and Respective Predictors in Pediatric CD 
 
Supplemental Figures 
 
Supplemental Figure 1. PRISMA diagram 
 
Supplemental Figure 2. Additional forest plots for predictors of surgery and B2/B3 
complications in pediatric CD: A – isolated colonic disease as a predictor of surgery; B – male 
sex as a predictor of surgery; C – ASCA positivity as a predictor of surgery; D – ASCA-IgA 
positivity as a predictor of B3 complications 
 
Supplemental Tables 
 
Supplemental Table 1. Characteristics of Studies Examining Predictor-Outcome Combinations 
Not Included in Meta-Analysis 
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Supplemental Table 2. Risk of Bias Studies Examining Predictor-Outcome Combinations Not 
Included in Meta-Analysis 
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Table 1. Characteristics of Studies Examining Predictor-Outcome Combinations Included in Meta-Analysis 
Study Study design Population 
IBD type 
Age, sex  
Predictors examined (definition, exposed vs 
unexposed) 
Outcomes examined (definition) Follow-up duration 
Aloi (2013) Retrospective, single center 36 pediatric CD 
Mean 14.7 (±4.12) y, 67% 
M 
Disease location 
ASCA+ (IgA or IgG) 
B2 (early stricture within 3 months of diagnosis) 
Surgery 
Intensified treatment 
Mean 2.48 (SD 
4.12) y 
Ammoury 
(2011) 
Retrospective, single center 81 pediatric CD 
Mean 11.6 (range 4–18) y, 
63% M 
Esophageal involvement Surgery Mean 3.5 y (range 
6 mo–10 y) 
Amre (2006) Retrospective, single center 139 pediatric CD 
Mean 11.2 (SD 3.4) y, 52% 
M 
Sex 
Disease location (SB only, colon only, SB and 
LB) 
ASCA (IgA, IgG, positivity, and titer) 
B3 (fistula or abscess) 
Surgery (ileocecal resection, perianal abscess drainage ± 
fistulectomy) 
Mean 5.8 (SD 3) y 
Attard (2004) Retrospective, single center 134 pediatric CD 
Mean 12.0 (SEM 1.2) y 
Jejunoileitis Surgery 
Hospitalization 
N/A 
Birimberg-
Schwartz (2016) 
Retrospective, multicenter 406 pediatric IBD (mixed 
cohort) 
Mean 10.5 (SD 3.9) y, 54% 
M 
Serology (ASCA, pANCA) Surgery 
Intensified treatment (biologic or calcineurin inhibitor) 
Median 2.8 (IQR 
1.6-4.2) y 
Chhaya (2015) Retrospective, multicenter 1595 pediatric CD Age (0–9 vs 10–13 vs 14–16 vs 17–24 y) 
Sex 
Surgery (resection, stricturoplasty, stoma creation) Mean 4.3 y 
Cucchiara (2007, 
WJG) 
Retrospective, multicenter 200 pediatric CD 
Mean 12 (SD 4) y, 58% M 
Genetics (NOD2/CARD15 variant) Surgery (resection) Median 2.8 y 
(range 1 d-16.7 y) 
De Greef (2013) Retrospective, multicenter 155 pediatric CD 
Median 12.5 (range 1.6-18) 
y, 55% M 
Gestational age, family history of IBD, disease 
severity at diagnosis, disease 
location/behavior 
Height and BMI z-score at diagnosis 
Height and BMI z-score over F/U 
PCDAI, PGA, surgery (IBD-related), medication use 
Median 2.7 (range 
0.3-8.2) y 
Desir (2004) Combined retrospective and 
prospective, single center 
61 pediatric CD 
Mean 10.7 (3.4) y, 49% M 
ASCA (IgA, IgG, positivity, and titer) B3 (fistula or abscess) 
Surgery (small or large bowel) 
Relapse  
Mean 4.9 (SD 2.1) y 
Dubinsky (2006) Prospective, multicenter 167 pediatric CD 
Median 12 (range 1–18) y, 
47% M 
ASCA, OmpC, I2 and/or CBir1 
Antibody sum score 
B2 or B3 Median 18 (range 
1–200) mo 
Dubinsky (2008) Prospective, multicenter 536 pediatric CD 
Median 12 (range 0.6–18) 
y, 56% M 
ASCA, OmpC, CBir1 B2 or B3 
Surgery (small or large bowel resection, perianal surgery) 
Median 32 mo 
Eidelwein (2007) Retrospective, single center 137 pediatric CD, mixed 
cohort 
Mean 12.6 (SD 4.1) y, 47% 
M (Black) 
Mean 11.6 (SD 4.5) y, 52% 
M (White) 
Race (Black vs White) B2 or B3 
Growth (weight- and height-for-age z-score) 
Medication use 
Surgery (colectomy, intestinal resection, ileostomy, 
fistulectomy) 
Mean 5.3 (SD 3.0) y 
(Black) 
Mean 4.8 (SD 3.2) y 
(White) 
(Growth at 1 y) 
Fabian (2017) Retrospective, single center 63 pediatric CD 
Median 12 (range 11–15) y, 
57% M 
Age (continuous) Complications (stricture that cannot be passed or with 
upstream dilatation, internal fistula or abscess, perianal fistula 
or anti-TNFα use) 
1 y 
Ferraris (2006) Retrospective, multicenter 134 pediatric CD 
Median 12 (IQR 9.5–13) y, 
51% M 
Genetics (NOD2/CARD15 variant) B2, B3 
Surgery (abdominal surgery) 
N/A 
Gupta (2006) 
 
Retrospective, multicenter 989 pediatric CD 
Mean 11.5 (SD 3.8) y, 57% 
Sex, age (0–2, 3–5, 6–12, 13–17 y) 
Ethnicity (Caucasian, Black, Asian/Pacific 
Surgery (partial SB resection, partial/total colectomy) Mean 3.6 (SD 3.1) y 
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M Islander, Hispanic, other)  
Poor growth (at presentation, not further 
defined) 
Disease location, severity (PCDAI) Granuloma, 
serologies  
Gupta (2008) Retrospective (registry), 
multicenter 
989 pediatric CD 
Mean 11.5 (SD 3.8) y, 57% 
M 
Age (6–17 vs 0–5 y) 
Poor growth (at presentation, not further 
defined) 
B2, B3 (fistula, abscess), perianal fissure 
Medication use 
Growth failure (height-for-age or height velocity <5th 
percentile) 
Compression fracture or osteopenia/osteoporosis  
Intensified treatment 
Median 2.8 y 
(range 1 d – 16.7 y) 
Gupta (2010) Retrospective (registry), 
multicenter 
989 pediatric CD 
Mean 11.5 (SD 3.8) y, 57% 
M  
Disease location (isolated SB vs SB + colonic 
vs isolated colonic) 
B2, B3 Median 2.8 y 
(range 1 d – 16.7 y) 
CI reported at 10 y 
Henderson 
(2015) 
Retrospective, multicenter 181 CD 
Median 11.6 y (9.5–13.1), 
57% M 
Age (0–9 vs 10–16 y) 
CRP at diagnosis 
Surgery Median 5.2 y 
Herman (2017) Retrospective, single center 209 pediatric CD 
Median 14.2 (IQR 12–16) y, 
58% M 
Perianal disease (fistulizing or non-fistulizing) B2 or B3 Median 8.5 (IQR 
5.2–11.7) y 
Ideström (2005) Retrospective, single center 58 pediatric CD 
Median 10.9 (range 2.8–
16.9) y, 62% M 
Genetics (NOD2/CARD15 variant) B2 
Surgery (luminal for stricture/fistula, not perianal) 
 
Median 4.2 (range 
0.9–9.7) y 
Jakobsen (2014) Case control 244 pediatric CD (mixed IBD 
cohort) 
Median 13.4 (11.6–14.0) y, 
54% M  
Genetics (NOD2/CARD15 variant) Surgery Median 4.7 y (3–7) 
y (entire IBD 
cohort) 
Kugathasan 
(2004) 
Prospective, multicenter 163 pediatric CD (138 with 
CARD15 data) 
Mean 12.4 (range 3–18) y, 
58% M 
Genetics (NOD2/CARD15 variant) B2, B3 
Surgery (ileocolonic or ileal resection) 
Mean 39 (range 6–
88) mo 
Kugathasan 
(2017) 
Prospective, multicenter 913 pediatric CD 
Median 12.3–15.6 y, 62% M 
Age (continuous) 
Race (Black vs other) 
Disease location (ileal vs ileocolonic vs 
isolated colonic) 
Antimicrobial serologies 
Genetics (NOD2/CARD15 variant) 
B2, B3 Median 40–47 mo 
Lacher (2010) Prospective, multicenter 171 pediatric CD 
Mean 11.8 (SD 3.2) y, 67% 
M 
Genetics (NOD2/CARD15 variant) B2, B3 
Surgery (intestinal resection) 
Median 4.76 (range 
0.25–13.14) y 
Leonor (2007) 
 
Retrospective, single center 280 pediatric CD 
Median 11.9 (IQR 11.5–
12.28) y, 60% M 
Sex, ethnicity 
Disease location (small bowel disease vs 
ileocolon or colon) 
 
Surgery (SB resection, subtotal/total colectomy, abscess I/D, 
Hartmann diversion of biopsy fistula in ano) 
Median 3.27 (IQR 
3.02–3.52) y 
Li (2013) Retrospective, single center 107 pediatric IBD 
Mean 11.2 (± 4.1) y 
Race (SA vs other) B3 (fistula) 
Medication use 
Mean 4 (± 2.9) y 
Min 1 y 
Malmborg 
(2015) 
Retrospective, multicenter 161 pediatric CD 
32% <10 y, 59% M 
Age (>10 vs <10 y) 
Disease location (ileal or ileocolonic vs 
colonic) 
B2 or B3 (or surgery) Median 8.8 y 
Na (2015) Retrospective, single center 65 pediatric CD 
Mean 8.6 ± 8.6 y, 58% M 
Genetics (NOD2/CARD15 variant) B2 or B3 
 
N/A 
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Posovszky 
(2013) 
Prospective, single center 85 pediatric CD 
Median 22 (17–35) y group 
1; 20 (15–26) y group 2, 
54% M 
Genetics (NOD2/CARD15 variant) B2, B3 
Surgery 
Min 2 y 
Rieder (2012) Prospective, single center 59 pediatric CD 
Mean 152 (SD 43) mo, 61% 
M 
gASCA+ B2 or B3 (or perianal fistula) 
Surgery 
N/A 
Rinawi (2016, 
DLD) 
Retrospective, single center 174 pediatric CD 
13% <10 y, 74% 10–17 y, 
13% 17–18 y  
Age, sex 
Disease location (ileal vs other), microscopic 
involvement, granulomas 
Perianal disease (tags/fissures) 
Growth impairment (G1 vs G0 as per Paris 
classification) 
B2, B3 
Perianal disease 
Disease extension 
Median 16.4 (± 4.4) 
y 
Min 10 y 
Rinawi (2016, 
IBD) 
Retrospective, single center 482 pediatric CD, 13.8 ±3 y Sex 
Disease location (ileal, ileocolonic or colonic), 
disease behavior 
Growth impairment (G1 vs G0 as per Paris 
classification) 
Surgery (intestinal surgery, stricturoplasty or fistulectomy) Median 8.6 ± 6.6 y 
Russell (2005) Retrospective, multicenter 167 pediatric CD 
Median 11.5 y, 54% M 
Genetics (NOD2/CARD15 variant) B2, B3 
Surgery (any except exam under anesthesia) 
2 y 
Savoye (2012) Retrospective, multicenter 309 pediatric CD 
Median 14 (range 12–16) y, 
54% M 
Sex, age 
Disease location, behavior, perianal disease 
Diagnostic delay 
Growth delay, EIM 
“Disabling” CD – growth delay (BMI, weight or height <‒2 SDS), 
or 1 intestinal resection or 2 perianal interventions 
Median 8 (range 7–
12) y, min 5 y 
Schaefer (2010) 
 
Prospective, multicenter 498 pediatric CD  
5% 0–5y, 56% 6–12 y, 39% 
13–16y, 58% M 
Age, sex, ethnicity 
Family history of IBD 
Disease severity, disease behavior, distal 
disease (between transverse colon and 
rectum) vs other 
 
Surgery (intestinal resection with anastomosis or ostomy, 
including subtotal/total colectomy, stricturoplasty or 
appendectomy) 
Median 2 (95% CI 
1.75–2.25) y 
Shaoul (2009) Retrospective, single center  128 pediatric CD  
Mean 12.8 ± 3.8 y, 62% M 
Age (<10, 10–12, >12 y) 
Genetics (NOD2/CARD15 – multiple alleles or 
heterozygote) 
Disease location 
Ethnicity (Sephardic vs Ashkenazi Jews) 
B2, B3 
Surgery 
Mean 4.9 ± 3.6 y 
Min 2 y 
Strisciuglio 
(2014) 
Retrospective, single center 74 pediatric CD 
Median 11 (range 0.7–17.9) 
y, 66% M 
Genetics (NOD2/CARD15 variant) B2, B3 
Surgery 
Number of relapses 
Min 1 y 
Sun (2003) Retrospective, single center 55 pediatric CD 
Mean 11.2 (range 1–17.5) y 
Genetics (NOD2/CARD15 variant) B2, B3 
Surgery (intestinal resection) 
N/A 
Sykora (2006) Prospective, multicenter 46 pediatric CD 
Mean 15.3 (SD 2.8) y, 54% 
M 
Age (continuous) 
Disease location (isolated SB vs SB + colonic 
vs isolated colonic) 
Genetics (TNFα polymorphism) 
B2, B3 (internal fistula, inflammatory mass/abscess, perianal 
fistula) 
Surgery (luminal resection) 
N/A 
Tomer (2003) Retrospective, single center 101 pediatric CD 
Mean 11.8 (0.3–18) y, 66% 
M 
Genetics (NOD2/CARD15 variant) B2, B3 Mean 49 mo (range 
28 d – 141 mo) 
Vernier-
Massouille 
(2008) 
Retrospective, multicenter 404 pediatric CD 
Median 14 (range 12–16) y, 
54% M 
 
Sex, age 
Disease location (ileal or ileocolonic vs 
colonic), disease behavior 
Perianal disease 
Surgery (partial SB resection, partial/total colectomy) Median 84 (range 
52–124) mo 
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Growth delay (BMI ≤‒2 SD) 
Zwintscher 
(2015) 
Retrospective (health 
administrative database), 
multicenter 
7845 pediatric (<20 y) CD, 
mixed cohort 
Mean 15.6 (SD 3.9) y, 51% 
M 
Sex, age (0–5 vs 6–10 vs 11–15 vs 16–20 y) 
Perianal disease (fistula, abscess, fissure) 
B3 (complex fistula, entero-enteral fistula) 
Perianal disease 
Growth failure (ICD-9 code) 
Surgery 
N/A 
ASCA, anti-Saccharomyces cerevisiae antibodies; BMI, body mass index; CD, Crohn’s disease; CI, cumulative incidence; CRP, C-reactive protein; d, days; EIM, extraintestinal manifestations; F/U, follow-up; IBD, gASCA, anti-
glycan ASCA; inflammatory bowel disease; ICD, International Classification of Diseases; I/D, incision and drainage; Ig, immunoglobulin; IQR, interquartile range; LB, large bowel; M, male; mo, months; N/A, not available; 
pANCA, perinuclear antineutrophil cytoplasmic antibody; PCDAI, Pediatric Crohn’s Disease Activity Index; PGA, Physician Global Assessment; SA, South Asian; SB, small bowel; SD, standard deviation; SDS, standard 
deviation scores; SEM, standard error of the mean; TNF, tumor necrosis factor; y, year 
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Table 2. Risk of Bias for Studies Examining Outcomes Included in Meta-Analysis 
Study Representativeness of 
exposed cohort 
Representativeness of non-
exposed cohort 
Ascertainment of 
exposure 
Outcome not 
present at start 
Comparability of 
cohorts (up to 2 stars) 
Outcome 
assessment 
Follow-up 
long enough 
Loss to 
follow-up 
Overall risk of bias 
(number of stars) 
Aloi (2013) 1 1 1 0 0 1 1 1 6 
Ammoury (2011) 1 1 1 1 0 1 1 1 7 
Amre (2006) 1 1 1 1 2 1 1 1 9 
Attard (2004) 1 1 1 1 0 1 0 1 6 
Birimberg-Schwartz 
(2016) 
1 1 1 1 1 1 1 1 8 
Chhaya (2015) 1 1 1 1 2 1 1 1 9 
Cucchiara (2007) 1 1 0 0 1 1 1 1 6 
De Greef (2013) 1 1 1 1 0 1 1 1 7 
Desir (2004) 1 1 1 1 2 1 1 1 9 
Dubinsky (2006) 1 1 1 1 0 1 1 1 7 
Dubinsky (2008) 1 1 1 1 0 1 1 1 7 
Eidelwein (2007) 1 1 1 1 0 1 1 1 7 
Fabian (2017) 1 1 1 1 2 1 0 1 8 
Ferraris (2006) 1 1 1 0 0 1 0 1 5 
Gupta (2006) 1 1 1 1 2 1 1 1 9 
Gupta (2008) 1 1 1 0 0 1 0 1 5 
Gupta (2010) 1 1 1 0 0 1 1 1 6 
Henderson (2015) 1 1 1 1 2 1 1 1 9 
Herman (2017) 1 1 1 1 0 1 1 1 7 
Jakobsen (2014) 1 1 1 1 2 1 1 1 9 
Ideström (2005) 1 1 1 0 0 1 1 1 6 
Kugathasan (2004) 1 1 1 0 1 1 1 1 7 
Kugathasan (2017) 1 1 1 1 2 1 1 1 9 
Lacher (2010) 1 1 1 0 0 1 1 1 7 
Leonor (2007) 1 1 1 1 1 1 1 0 7 
Li (2013) 1 1 1 1 0 0 0 1 5 
Malmborg (2015) 1 1 1 1 2 1 1 1 9 
Na (2015) 1 1 1 0 0 1 0 1 5 
Posovszky (2013) 1 1 1 0 0 1 1 1 6 
Rieder (2012) 1 1 1 0 1 1 0 1 6 
Rinawi (2016, DLD) 1 1 1 1 1 1 1 1 8 
Rinawi (2016, IBD) 1 1 1 1 2 1 1 1 9 
Russell (2005) 1 1 1 0 2 1 1 1 8 
Savoye (2012) 1 1 1 1 1 1 1 0 7 
Schaefer (2010) 1 1 1 1 2 1 1 0 8 
Shaoul (2009) 1 1 1 0 0 1 1 1 6 
Strisciuglio (2014) 1 1 1 0 0 1 0 1 5 
Sun (2003) 1 1 1 0 0 1 0 1 5 
Sykora (2006) 1 1 1 0 0 1 0 1 5 
Tomer (2003) 1 1 1 0 0 1 1 1 6 
Vernier-Massouille 
(2008) 
1 1 1 1 2 1 1 1 9 
Zwintscher (2015) 1 1 1 0 1 0 0 1 5 
Based on Newcastle-Ottawa Scale 
All columns 0 or 1 stars except comparability (0 to 2), last column = total # of stars 
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Table 3. Findings from Individual Studies Examining Predictor-Outcome Combinations Included in Meta-Analysis 
Study Outcome Predictor (definition, 
exposed vs unexposed) 
Events Absolute effect Unadjusted relative effect Adjusted relative effect 
Events/ 
exposed 
Events/ 
unexposed 
OR (95% CI) HR (95% CI) p-value OR (95% CI)
1 
HR (95% CI) p-value 
Growth impairment as a predictor of surgery 
Gupta (2006) Surgery Growth impairment (not 
further defined) 
128/956    1.99 (1.18–
3.37) 
0.01  2.16 (1.24–
3.77) 
0.007 
*De Greef (2013)  Surgery Height- and BMI-for-age z-
score at diagnosis 
17/155     NS    
Rinawi (2016) Surgery Growth impairment (as 
per Paris classification) 
143/482 42/107 101/375  1.6 (1.1–2.3) 0.011   NS 
*Savoye (2012)  Surgery (composite 
outcome) 
Growth delay BMI, weight 
or height <‒2 SDS 
47/309     <0.05    
*Zwintscher (2015)
2 
Surgery Growth impairment (as 
per ICD-9) 
2,113/ 
12,465 
     1.21 (0.86–
1.71) 
 0.279 
Disease location as a predictor of surgery 
*Ammoury (2011) Surgery Esophageal involvement  9/81     0.09    
Amre (2006) Surgery Colon only vs other 35/139 4/32 31/107   0.07    
*Attard (2004) Surgery Jejunum or proximal ileum /134 11/23 12/111 3.7  <0.03    
*De Greef (2013) Surgery Disease location  17/155     NS    
Gupta (2006) Surgery L2 (colonic) vs L1 (isolated 
ileal) 
/600 /144 /456  0.56 (0.27–
1.16) 
0.12    
*Leonor (2007) Surgery Disease location 55/280     NS    
*Henderson (2015) Surgery Disease location /465     NS    
Rinawi (2016, IBD) Surgery Colon only vs other for 
proportions (2x2); L2 vs L1 
for HR 
143/482 7/58 136/424   0.003  0.70 (0.51–
0.96) 
0.03 
Schaefer (2010) Surgery Transverse colon to 
rectum vs other 
57/854 /674 /180     0.35 (0.19–
0.64) 
0.0007 
*Savoye (2012) Surgery (composite 
outcome) 
UGI disease 47/309     NS    
*Shaoul (2009) Surgery (Ileo)colonic disease 38/128     <0.04    
Vernier-Massouille 
(2008) 
Surgery L2 vs L1 176/353    0.60 (0.33-1.10) 0.1    
Sex as a predictor of surgery 
Aloi (2013) Surgery Male vs female 4/36 3/25 1/11   NS    
Amre (2006) Surgery Male vs female 35/139 15/72 20/67   NS    
Chhaya (2015) Surgery Male vs female /1,595    0.90 (0.69–
1.17) 
0.43    
Dubinsky (2008) Surgery Male vs female 140/796       0.59 (0.38–
0.91) 
<0.009 
Gupta (2006) Surgery Male vs female 128/989 63/566 65/423   NS  0.65 (0.46–
0.93) 
0.02 
Leonor (2007) Surgery Male vs female 55/280 35/167 20/113   NS    
Rinawi (2016) Surgery Male vs female 143/482 86/280 57/202  1.05 (0.75–
1.47) 
0.78  0.98 (0.68–
1.41) 
0.92 
Schaefer (2010) Surgery Male vs female 57/854 36/498 21/356   NS    
Vernier-Massouille 
(2008)  
Surgery Male vs female /394    0.96 (0.71–
1.30) 
0.77   NS 
*Zwintscher (2015)
2 
Surgery Male vs female 2,113/      1.17 (1.06–  0.001 
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12,465 1.30) 
NOD2/CARD15 polymorphisms as a predictor of surgery  
Cucchiara (2007) Surgery NOD2/CARD15 variant 50/196 23/75 27/121   NS    
*Dubinsky (2008) Surgery NOD2/CARD15 variant      NS    
Ferraris (2006) Surgery NOD2/CARD15 variant 12/134 4/50 8/84 0.83 (0.24–
2.90) 
 1    
*Jakobsen (2014) Surgery Genetic variants including 
NOD2/CARD15 variant 
/244     NS    
Kugathasan (2004) Surgery NOD2/CARD15 variant /163       7.78 (2.74–
22.1) 
<0.0005 
Lacher (2010) Surgery NOD2/CARD15 variant 32/171 21/78 11/93 2.75 (1.23–
6.14) 
 0.017    
*Posovsky (2013) Surgery NOD2/CARD15 variant /85 /37 /48   NS    
Russell (2005) Surgery NOD2/CARD15 variant 45/167 18/33  4.45 (1.98–
10.00) 
 0.0002    
*Shaoul (2009) Surgery NOD2/CARD15 variant 38/128 /48 /77   NS    
Strisciuglio (2014) Surgery NOD2/CARD 15 variant 10/74 2/16 8/58   0.89    
Sun (2003) Surgery NOD2/CARD15 variant 17/55 13/36 4/19   0.26    
Stricturing disease (B2) as a predictor of surgery 
De Greef (2013) Surgery B2 20/155   6.8 (1.8–25.3) 0.001     
Schaefer (2010) Surgery B2 57/854       6.60 (3.39–
12.86) 
<0.0001 
Vernier-Massouille 
(2008) 
Surgery B2 176/394 /96      2.54 (1.59–
4.05) 
<0.01 
Internal penetrating disease (B3) as a predictor of surgery 
Schaefer (2010) Surgery B3 57/854       3.70 (1.80–
7.60) 
0.0005 
Vernier-Massouille 
(2008) 
Surgery B3 176/394 /11      1.28 (0.33–
4.89) 
0.72 
Stricturing and/or internal penetrating disease (B2/B3) as a predictor of surgery 
Rinawi (2016) Surgery B2 and/or B3 143/482 51/115 92/367 2.38 (1.54–
3.69) 
   2.44 (1.69–
3.53) 
<0.001 
Antimicrobial serologies as a predictor of surgery 
Amre (2006) Surgery ASCA+ (IgA or IgG) 35/139 24/75 11/64   0.05  1.80 (0.84–
3.85) 
<0.05 
*Birimberg-
Schwartz 
Surgery pANCA-/ASCA+ 6/146     0.326    
*Desir (2004) Surgery ASCA IgG /154   2.34 (0.29–
18.5) 
     
Dubinsky (2008) Surgery ASCA+ 61/563   2.2 (1.5–3.2)  0.0001  
 
3.2 (1.1–9.5) <0.04 
Gupta (2006) Surgery ASCA+ /161 7/63 /98  3.43 (1.00–
11.76 
0.05    
Rieder (2012) Surgery gASCA+ 20/59  /22    1.4 (0.4–5.0)
2 
1.9 (0.55–6.4)
3 
2.5 (0.64–9.4)
4
 
 0.59 
0.32 
0.19 
Rinawi (2016) Surgery ASCA+ 94/170 25/32 69/138  3.10 (1.34–
7.19) 
0.008   NS 
Russell (2009) Surgery ASCA+ 49/197 27/82 22/115 2.11 (1.10–
4.06) 
 0.03    
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Age as a predictor of stricturing (B2) disease  
*Gupta (2008) B2 Age (6–17 vs 0–5 y) /989 /857 /83  2.15 (0.99–
4.69) 
0.05    
*Kugathasan (2017) B2 Age (continuous) 54/913       1.07 (0.97–1.17) 0.16 
*Shaoul (2009) B2 Age (<10, 10–12, >12 y) 20/128     NS    
Race as a predictor of stricturing (B2) disease 
*Kugathasan (2017) B2 Black vs other 54/913 9/121 45/792   0.45  1.08 (0.52–2.22) 0.84 
Disease location as a predictor of stricturing (B2) disease 
*Aloi (2013) B2 Disease location /36     NS    
Gupta (2010) B2 Ileal or ileocolonic vs colon 
only 
/600 103/456 16/144  CI at 10 y 39.3 
(14.1–80.6) 
(ileal) vs 18.7 
(13.1–26.3) 
(ileocolonic) vs 
11.4 (4.9–25) 
(colon only) 
0.02    
Kugathasan (2017) B2 Ileal or ileocolonic vs colon 
only for proportions; 
isolated ileal vs other for 
HR 
54/913 44/690 10/223   0.30  1.60 (0.88–2.91) 0.12 
Antimicrobial serologies as a predictor of stricturing (B2) disease 
*Aloi (2013) B2 ASCA+ (IgA or IgG) /36     NS    
*Kugathasan (2017) B2 ASCA IgA+ 54/913 22/218 32/695   0.003  1.69 (0.94–3.07) 0.0816 
*Kugathasan (2017) B2 CBir1+ 54/913 32/341 22/572   <0.001  2.30 (1.26–4.20) 0.007 
NOD2/CARD15 polymorphisms as a predictor of stricturing (B2) disease 
Ferraris (2006) B2 NOD2/CARD15 variant 22/134 8/50 14/84 1.03 (0.39–
2.69) 
 0.95    
*Ideström (2005) B2 NOD2/CARD15 variant 7/58 /5 /53   NS    
Kugathasan (2004) B2 NOD2/CARD15 variant 25/138 20/58 5/80   0.0001 7.9 (2.94–
25.21)
4 
 0.0001 
*Kugathasan (2017) B2 NOD2/CARD15 variant 54/913     0.14    
Lacher (2010) B2 NOD2/CARD15 variant 29/171 23/78 6/93 6.06 (2.32–
15.83) 
 <0.000
1 
   
*Na (2015) B2 NOD2/CARD15 variant      NS    
Posovszky (2013) B2 NOD2/CARD15 variant 21/85 15/37 6/48   0.005    
Russell (2005) B2 NOD2/CARD15 variant 7/167 3/33 4/134   0.14    
Shaoul (2009) B2 NOD2/CARD15 (multiple 
alleles or heterozygote, 
any variant) 
20/125 8/48 12/77   0.87    
Strisciuglio (2014) B2 NOD2/CARD15 variant 8/74 5/16 3/58   0.01    
Sun (2003) B2 NOD2/CARD15 variant 24/55 18/36 6/19 2.17 (0.67–
6.96) 
 0.4    
Tomer (2003) B2 NOD2/CARD15 variant 2/101 1/29 1/72   0.5    
Age as a predictor of internal penetrating (B3) disease 
*Gupta (2008) B3 (fistula) Age (6–17 vs 0–5 y) /989 /857 /83  2.67 (1.15–
6.15) 
0.02    
*Gupta (2008) B3 (abscess) Age (6–17 vs 0–5 y) /989 /857 /83  7.66 (2.36–
24.9) 
0.001    
*Kugathasan (2017) B3 Age (continuous) 24/913       1.45 (1.17–1.80) 0.0008 
*Shaoul (2009) B3 Age (<10, 10–12, >12) 8/128     NS    
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*Zwintscher (2015) B3 (complex fistula) Age (0–5 vs 6–10 vs 11–15 
vs 16–-20 y) 
98/7,845 
 
       0.994 
*Zwintscher (2015) B3 (entero-enteral 
fistula) 
Age (0–5 vs 6–10 vs 11–15 
vs 16–20 y) 
293/ 
7,845 
       0.994 
Race as a predictor of internal penetrating (B3) disease 
Kugathasan (2017) B3 Black vs White 24/913 9/121 15/792   0.001  3.19 (1.39–7.31) 0.0061 
Li (2013) B3 SA vs White 15/107 3/13 12/94  CI 15.4 (4.1–
4.8) vs 4.4 (1.7–
11.4) 
0.02    
Disease location as a predictor of internal penetrating (B3) disease 
*Gupta (2010) B3 Ileal or ileocolonic vs colon 
only 
/600 /456 /144   0.13    
*Kugathasan (2017) B3 Ileal or ileocolonic vs colon 
only for proportions; 
isolated ileal vs other for 
HR 
24/913 21/690 3/223   0.18  1.23 (0.51–2.95) 0.64 
Antimicrobial serologies as a predictor of internal penetrating (B3) disease 
Amre (2006) B3 ASCA IgA+ 31/139 23/67 8/72   0.002  2.84 (1.20–6.72) <0.05 
*Desir (2004) B3 ASCA IgA+ 13/61      0.51 (0.08–
3.08) 
 NS 
Kugathasan (2017) B3 ASCA IgA+ 24/913 14/218 10/695   0.0002  2.68 (1.19–6.04) 0.0171 
*Amre (2006) B3 ASCA IgA titer 31/139       1.20 (1.08–1.34) <0.005 
*Desir (2004) B3 ASCA IgA titer 13/61      1.04 (0.29–
3.76) 
 NS 
Amre (2006) B3 ASCA IgG+ 31/139 17/59 14/80   0.12  2.38 (1.09–5.17) <0.05 
Desir (2004) B3 ASCA IgG+ 13/61      0.72 (0.14–
4.22) 
 NS 
*Amre (2006) B3 ASCA IgG titer 31/139       1.12 (0.99–1.28) NS 
*Desir (2004) B3 ASCA IgG titer 13/61      0.91 (0.29–
2.75) 
 NS 
*Amre (2006) B3 ASCA IgA+ or IgG+ 31/139 23/75 8/64   0.01  2.33 (0.99–5.50) NS 
*Kugathasan (2017) B3 CBir1+ 24/913 16/341 8/572   0.005  3.01 (1.31–6.93) 0.0097 
Perianal disease as a predictor of internal penetrating (B3) disease 
*Zwintscher (2015) B3 (complex fistula) Perianal disease (abscess, 
fissure, fistula) 
 
98/7,845 
 
     3.50 (1.98–
6.20) 
 <0.001 
*Zwintscher (2015) B3 (entero-enteral 
fistula) 
Perianal disease (abscess, 
fissure, fistula) 
293/ 
7,845 
     0.30 (0.15–
0.63) 
 0.001 
NOD2/CARD15 polymorphisms as a predictor of internal penetrating (B3) disease 
Ferraris (2006) B3 NOD2/CARD15 variant 14/134 7/50 7/84 1.8 (0.58–5.55)  0.3    
Kugathasan (2004) B3 NOD2/CARD15 variant 24/138 8/58 16/80   0.34 0.64 (0.24–
1.58)
4 
 0.345 
*Kugathasan (2017) B3 NOD2/CARD15 variant 54/913     0.39    
Lacher (2010) B3 NOD2/CARD15 variant 2/171 2/78 0/93   0.24    
*Na (2015) B3 NOD2/CARD15 variant      NS    
Posovszky (2013) B3 NOD2/CARD15 variant 21/85 6/37 3/48   0.16    
Russell (2005) B3 NOD2/CARD15 variant 24/167 7/33 17/134   0.22    
Shaoul (2009) B3 NOD2/CARD15 (multiple 
alleles or heterozygote, 
any variant) 
8/125 5/48 3/77   0.16    
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Strisciuglio (2014 B3 NOD2/CARD15 variant 4/74 4/16 0/58   0.01    
Sun (2003) B3 NOD2/CARD15 variant 12/55 7/36 5/19 0.68 (0.18–
2.51) 
 0.82    
Tomer (2003) B3 NOD2/CARD15 variant 19/101 3/29 16/72   0.18    
Age as a predictor of stricturing and/or internal penetrating (B2/B3) disease  
*Fabian (2017) B2 or B3 (or perianal 
fistula or anti-TNF) 
Age (continuous) 19/63      RR 0.95 (0.85–
1.05) 
 0.29 
*Malmborg (2015) B2 or B3 (or anti-
TNF use) 
Age (>10 vs <10 y) /161 /51 /110  1.81 (0.83–
3.99) 
0.14  1.00 (0.35–2.85) 0.99 
*Rinawi (2016) B2 or B3 Age (continuous) 80/174    1.02 0.47   NS 
*Sykora (2006) B2 or B3 (or perianal 
fistula) 
Age 16/46     NS    
Race as a predictor of stricturing and/or internal penetrating (B2/B3) disease 
*Eidelwein (2007) B2 or B3 Race (Black vs White) 21/137 10/34 11/103   0.01    
Disease location as a predictor of stricturing and/or internal penetrating (B2/B3) disease 
Gupta (2010) B2 or B3 Ileal or ileocolonic vs colon 
only 
/600 207/456 32/144  CI at 10 y 57.7 
(33.5–83.6) 
(ileal) vs 42.5 
(32.9–53.7) 
(ileocolonic) vs 
22.4 (14.4–
33.8) (colon 
only) 
0.0009    
*Malmborg (2015) B2 or B3 (or anti-
TNF use) 
Ileal or ileocolonic vs colon 
only 
/161 /130 /31  1.38 (0.63–
3.03) 
0.44    
Rinawi (2016) B2 or B3 Ileal or ileocolonic vs other 
for proportions; isolated 
ileal vs other for HR 
80/173 63/127 17/46  1 0.52    
Sykora (2006) B2 or B3 (or perianal 
fistula) 
Isolated SB or SB + colonic 
vs colon only 
16/46 14/41 2/5   0.80    
Antimicrobial serologies as a predictor of stricturing and/or internal penetrating (B2/B3) disease 
Dubinsky (2006) B2 or B3 Seropositive (ASCA, OmpC, 
I2 and/or CBir1+)  
10/167 8/97 2/70   0.03 
(log-
rank) 
   
Dubinsky (2008) B2 or B3 Seropositive (ASCA, OmpC 
and/or CBir1+)  
37/536 32/363 5/173   0.01    
*Dubinsky (2008) B2 or B3 Antibody sum score (1–3 
for each positive antibody 
vs 0) 
37/536    1.1 (0.3–3.7) 
5.5 (2.0–15.2) 
6.0 (1.7–20.5) 
NS 
0.005 
<0.005 
   
*Dubinsky (2008) B2 or B3 ASCA+ 37/536     NS    
*Dubinsky (2008) B2 or B3 OmpC+ 37/536    2.4 (1.2–4.9) 0.01    
*Dubinsky (2008) B2 or B3 CBir1+ 37/536    2.5 (1.2–5.2) <0.02    
*Rieder (2012) B2 or B3 (or perianal 
fistula) 
gASCA+ /59 /37 /22    7.4 (1.4–38.2)
2 
3.9 (1.08–13.8)
3 
2.5 (0.68–9.0)
4 
0.016 
0.038 
0.17 
 
Perianal disease as a predictor of stricturing and/or internal penetrating (B2/B3) disease 
Herman (2017) B2 or B3 Perianal disease (fistulizing 
or non-fistulizing) 
29/209 18/71 11/138   0.001    
Rinawi (2016) B2 or B3 Perianal disease 
(tags/fissures) 
80/174 10/22 70/152  0.97 0.92    
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*Denotes specific predictor-outcome pairs that could not be meta-analyzed due to heterogeneity or insufficient data, including lack of CD-specific data 
ASCA, anti-Saccharomyces cerevisiae antibodies; BMI, body mass index; CI, cumulative incidence; gASCA, anti-glycan ASCA; HR, hazard ratio; ICD, International Classification of Diseases; Ig, immunoglobulin; NS, not 
significant; OR, odds ratio; pANCA, perinuclear antineutrophil cytoplasmic antibody; RR, relative risk; SA, South Asian; SB, small bowel; SDS, standard deviation scores; TNF, tumor necrosis factor; UGI, upper gastrointestinal 
1 
Unless otherwise stated to be RR 
2 
Adjusted for disease location 
3 
Adjusted for disease duration 
4 
Adjusted for age 
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Table 4. Summary of Outcomes and Respective Predictors in Pediatric CD 
Outcomes Predictors Possible predictors No association 
Surgery • Growth impairment 
• Presence of genetic variants 
• ASCA (+) 
• Adolescent diagnosis 
• Disease location 
• Ethnicity 
• Presence of granulomas  
• Sex 
Stricturing 
(B2)/Penetrating 
(B3) disease 
• Ethnicity (B3) 
• Isolated small bowel disease (B2) 
• ASCA (+) and higher ASCA IgA titer 
(B3) 
• CBir1 (+) (B2/B3) 
• ≥1 microbial seropositivity (B2/B3) 
• NOD2/CARD15 polymorphisms (B2) 
• Older age at diagnosis (B3) 
• Isolated small bowel disease (B3) 
• Perianal disease (B2/B3) 
• Older age at diagnosis (B2) 
• ASCA-IgA (B2) 
• Sex (B2/B3) 
• Family history of IBD (B2/B3) 
• Disease activity at baseline (B2/B3) 
• Granulomas (B2/B3) 
• Upper GI tract involvement 
(B2/B3) 
• EIM (B2/B3) 
• Diagnostic delay (B2/B3) 
Perianal disease • Ethnicity • Older age at CD onset 
• Bacterial serology 
• Sex 
• Genetics 
• ANCA (+) 
• Anthropometric parameters 
• Disease location 
• Disease behavior 
• EIM 
• Diagnostic delay 
• Disease activity 
Linear growth 
impairment 
• More active disease at baseline or 
over time 
• Diagnostic delay 
• Male sex  
• Younger age at CD onset 
• Isolated small bowel disease 
• NOD2/CARD15 polymorphisms 
• EIM 
• Pubertal status  
• Family history of IBD 
• Ethnicity 
• Gestational age 
• Upper GI tract involvement 
• Oral involvement 
• Granulomas 
• Disease behavior 
• Perianal disease 
• Presenting symptoms 
Bone disease • Poor nutritional status (via height, 
weight, BMI) 
• Higher clinical disease activity 
(PCDAI at baseline and over time) 
• Sex 
• Disease location 
• Disease behavior 
• EIM 
• Granulomas 
• Perianal disease 
Chronically active 
inflammatory 
disease 
 • ASCA positivity  
• Microscopic ileocolonic 
involvement 
• Disease activity 
• Disease behavior (B2/B3) 
• Age 
• Sex 
• Ethnicity 
Hospitalization  • Disease behavior (B2/B3) 
• Granulomas 
• Increased visceral adipose tissue 
• Age 
• Small bowel involvement 
• TNF polymorphisms 
• NOD2 variants 
Future disease 
activity or severity 
N/A 
Number of relapses N/A 
ANCA, anti-neutrophil cytoplasmic antibody; ASCA, anti-Saccharomyces cerevisiae antibodies; B2, stricturing disease; B3, penetrating disease; 
BMI, body mass index; CD, Crohn’s disease; EIM, extraintestinal manifestations; GI, gastrointestinal; IBD, inflammatory bowel disease; Ig, 
immunoglobin; N/A, not available; PCDAI, Pediatric Crohn’s Disease Activity Index; TNF, tumor necrosis factor 
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Supplemental Materials for Crohn’s Disease (CD) 
Supplemental Methods 
Search string for Cochrane 
(‘crohn*’ or ‘ulcerative colitis’ or ‘inflammatory bowel diseas*’ or ‘IBD’) and ((infant or pediatric 
or paediatric or adolescent or teenagers or teens) and (predict* or prognos* or surgery or 
colectomy or resection or ‘steroid depend*’ or hospitalization* or complication or stenosis or 
fistul* or ‘penetrat*’ or growth or height or osteopenia or osteoporosis or ‘acute severe colitis’ 
or cancer or malignancy or lymphoma or ‘colorectal carcinoma’ or ‘colorectal cancer’ or ‘colon 
cancer’ or adenocarcinoma or death or mortality or outcome or ‘quality of life’ or melanoma)) 
 
Search string for Embase 
‘crohn*’ OR ‘ulcerative colitis’ OR ‘inflammatory bowel diseas*’ OR ‘ibd’ AND (infant OR 
pediatric OR paediatric OR adolescent OR teenagers OR teens) AND (predict* OR prognos* OR 
surgery OR colectomy OR resection OR ‘steroid depend*’ OR hospitalization* OR complication 
OR stenosis OR fistul* OR ‘penetrat*’ OR growth OR height OR osteopenia OR osteoporosis OR 
‘acute severe colitis’ OR cancer OR malignancy OR lymphoma OR ‘colorectal carcinoma’ OR 
‘colorectal cancer’ OR ‘colon cancer’ OR adenocarcinoma OR death OR mortality OR outcome 
OR ‘quality of life’ OR melanoma) AND [english]/lim AND [1992-2017]/py 
Search string for PUBMED 
(“crohn$”[Mesh Terms] OR “crohn$”[all fields] ) 
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OR (“ulcerative colitis”[Mesh Terms] OR “ulcerative colitis”[all fields] OR UC[Mesh Terms] OR 
UC[all fields]) OR (“inflammatory bowel diseas$”[Mesh Terms] OR “inflammatory bowel 
diseas$”[all fields] OR “IBD”[Mesh Terms] OR “IBD”[all fields])) 
AND ( (infant[mesh] OR pediatric[mesh] OR paediatric[mesh] OR adolescent[mesh] OR 
teenagers[mesh] OR teens[mesh]) AND ( predict$[all fields] OR prognos$[all fields] OR 
surgery[all fields] OR colectomy[all fields] OR resection[all fields] OR “steroid depend$”[all 
fields] OR hospitalization$[all fields] OR complication[all fields] OR stenosis[all fields] OR 
fistul$[all fields] OR penetrat$[all field] OR growth[all fields] OR height[all fields] OR 
osteopenia[all fields] OR osteoporosis[all fields] OR “acute severe colitis”[all fields] OR 
cancer[all fields] OR malignancy[all fields] OR lymphoma[all fields] OR “colorectal 
carcinoma”[all fields] OR “colorectal cancer”[all fields] OR “colon cancer”[all fields] OR 
adenocarcinoma[all fields] OR death[all fields] OR mortality[all fields] OR outcome[all fields] OR 
“quality of life”[all fields] OR melanoma[all fields]))) AND english[la] AND 
“1992/01/01”[pdat]:“2017/06/01”[pdat] 
 
Supplemental Results 
Prognostic Factors for Surgery 
Statement 1.1. Diagnosis in adolescence (>13 years of age), compared with younger age, may 
predict increased risk of bowel surgery within 5 years of diagnosis (94% agreement). 
Age at diagnosis was examined as a risk factor for surgery in multiple studies, with 
conflicting outcomes. In a registry study (the Pediatric IBD Consortium Registry), risk of surgery 
significantly increased with age among 989 children with CD diagnosed between 0 and 17 years 
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(adjusted hazard ratio [aHR] 1.12 per 1-year increase in age, 95% confidence interval [CI] 1.06–
1.18, P<.0001). The children were divided into four age groups (0–2, 3 –5, 6–12, and 13–17 
years), with risk for surgery significantly higher among children diagnosed at a younger age than 
among those diagnosed at 13–17 years (age of diagnosis 3–5 years: hazard ratio [HR] 0.20, 95% 
CI 0.07–0.57, P=.003; age of diagnosis 6–12 years: HR 0.53, 95% CI 0.36–0.77, P=.0008).1 In 
contrast, data from 854 children with CD from the Pediatric Inflammatory Bowel Disease 
Collaborative Research Group indicated that older age at diagnosis was significantly associated 
with increased risk of bowel surgery, including intestinal resection, strictureplasty, or 
appendectomy (HR 1.1, 95% CI 1.01–1.03, P=.042).2 Similarly, a 5-year follow-up study of 
children with IBD (19 with CD) found that children who had surgery owing to stricturing disease 
(mean age 11.0 years, 95% CI 8.0–14.0) were significantly younger at diagnosis than children 
who had not received surgery (mean age 14.2 years, 95% CI 13.3–15.1, P=.03).
3
 
Age was not significantly associated with risk for surgery across seven studies. In a study of 
506 children with IBD, risk for surgery was equal across three groups (0–5 years, 6–11 years, 
and 12–18 years).4 A United Kingdom retrospective study of patients with IBD (1,595 with CD) 
reported no significant difference in risk for surgery between those diagnosed at 14–16 years 
and those diagnosed at 17–24 years (HR 1.34, 95% CI 0.95–1.89, P=.09).5 In a natural history 
study of 404 children with CD, the risk for surgery was not significantly different among children 
diagnosed at <10 years at diagnosis (HR 0.66, 95% CI 0.36–1.21, P=.18).
6
 Four studies with 
smaller numbers of CD patients who underwent surgery also found age not to be a significant 
predictor.
7-10
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Statement 1.2. Growth impairment at diagnosis predicts increased risk of bowel surgery (81% 
agreement). 
Growth impairment, as assessed by weight, height, and body mass index (BMI), was 
consistently identified as a risk factor for surgery in multiple studies. 
In the natural history study of CD described earlier, growth delay (BMI ≤2 standard 
deviations [SD]) was associated with an increased risk of first resection surgery (HR 1.68, 95% CI 
1.16–2.44, P=.01).6 A chart review of 482 children with CD reported a significantly increased risk 
for children with growth impairment at diagnosis (HR 1.6, 95% CI 1.1–2.3, P=.011), particularly 
for lower weight z-score at diagnosis (HR 0.86, 95% CI 0.75–0.99, P=.035).11 In the Pediatric IBD 
Consortium Registry study, poor growth (based on clinicians’ observations) was the only 
symptom at disease onset that was significantly associated with risk for surgery (HR 1.99, 95% 
CI 1.18–3.37, P=.01). This association remained significant when multivariate Cox modeling was 
applied (HR 2.16, 95% CI 0.26–0.94, P=.007).1 
Of note, an analysis of 12,465 inpatient admissions for patients aged ≤20 years with IBD in 
2009 (Kids’ Inpatient Database) found that growth failure or overall developmental delay 
(defined as lack of development, failure to thrive, delayed milestones, or short stature) did not 
affect the likelihood of surgical intervention,10 and a Belgium registry study of 255 children with 
CD found that height and BMI were not significantly related to the need for surgery.
9
 
 
Statement 1.3. Disease location may predict surgery; isolated colonic disease is associated 
with fewer surgeries (84% agreement). 
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Distal disease was found to be protective in 854 children with CD from the Pediatric 
Inflammatory Bowel Disease Collaborative Research Group who were diagnosed with CD 
between 2002 and 2008. The presence of disease between the transverse colon and rectum 
was significantly associated with a decreased risk of surgery (P<.015), and in the subgroup of 
790 patients with disease in the ileum and/or right colon, additional disease involvement 
between the transverse colon and rectum was associated with a decreased risk of bowel 
surgery (P<.004). In addition, distal disease was significantly associated with a decreased risk for 
surgery (HR 0.4, 95% CI 0.2–0.6, P=.007), whereas increased risks for surgery were associated 
with stricturing disease (HR 6.6, 95% CI 3.4–12.9, P<.0001), penetrating disease (HR 3.7, 95% CI 
1.8–7.6, P=.0005), and disease severity (defined as an increase in physician global assessment 
[PGA], HR 2.6, 95% CI 2.0–3.5, P<.0001).2 Furthermore, in 224 CD patients diagnosed at <20 
years (mean follow-up 12.2 years), patients with only localized colonic disease were less likely 
to require intestinal resection (P<.05).12 
 
Statement 1.4. Inconclusive evidence exists for sex as a predictor for surgery; presence of 
NOD2/CARD15 variants, stricturing and/or internal penetrating (B2/B3) phenotype, and 
positive anti-Saccharomyces cerevisiae antibodies (ASCA) status predict surgery; ethnicity and 
presence of granulomas at diagnosis do not predict surgery (90% agreement). 
Results were inconsistent regarding the role of sex as a predictor for surgery. An analysis of 
2,113 surgeries performed across 12,465 patients from the Kid’s Inpatient Database reported a 
lower risk for surgery in girls.
10
 In contrast, girls were found to be at a significantly increased 
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risk for surgery in a separate analysis of the Pediatric IBD Consortium Registry data (n=989).1 
Sex was not found to be a significant predictor for surgery in five additional studies.
5-7, 11, 13
 
Evidence for NOD2/CARD15 gene variants as a predictor of risk for surgery was mixed 
across studies. A study of 186 patients found that a 3020insC mutation conferred a higher risk 
for surgery.14 A study of 32 patients undergoing surgery identified a need for significantly 
earlier surgery in 15 patients with a p.1007fs mutation.
15
 In a retrospective study, a higher 
proportion of patients who underwent intestinal surgery than those who did not had one or 
more single nucleotide polymorphisms (SNPs) in NOD2/CARD15.
16
 A large genotypic association 
study in a mixed population of adults and children, which included 2,568 CD patients of age <17 
years, found that, though there was a strong association between NOD2 and surgery, this was 
no longer the case after controlled for disease location.17 Additional pediatric studies also 
observed no association between gene variants and risk for surgery.
18-24
 
Complicated disease increases the risk for surgery. Stricturing disease, enteroenteral fistulas, 
and complex fistulas (rectourethral, rectovaginal, or enterovesical) significantly increased the 
risk for surgery.6, 10, 11 
Circulating microbial antibodies were identified as potential predictors for surgery. In five 
studies the association between a positive ASCA status and surgery was significant or bordered 
the null.
1, 11, 13, 25, 26
 In a retrospective chart review of children with CD from the Schneider 
Pediatric Inflammatory Bowel Disease cohort identified between 1996 and 1998, a positive 
ASCA status or ASCA+/perinuclear antineutrophil cytoplasmic antibody (pANCA)(–) profile was 
significantly associated with an increased risk for surgery.
11
 In a study of a panel of circulating 
microbial antibodies, only antilaminaribioside carbohydrate antibodies (ALCA) was positively 
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associated with CD-related surgery after controlling for age.27 Other small studies did not find 
any association between ASCA or pANCA and surgery.
28, 29
 
Ethnicity was consistently not associated with risk for surgery.1, 2, 30, 31 
The presence of granulomas was not a predictor for surgery in any of the five studies in 
children with CD.1, 11, 32-34 
 
Prognostic Risk Factors for Complications in Pediatric CD 
Statement 2.1. Children who develop CD at an older age may be at increased risk of 
developing internal penetrating (B3) complications, but not stricturing (B2) disease (94% 
agreement). 
Age at diagnosis was a risk factor for progression to complicated CD, particularly internally 
penetrating complications. In 989 children with CD from the American Pediatric IBD Consortium 
Registry, children aged 6–17 years were at higher risk of developing fistulas (HR 2.67, 95% CI 
1.15–6.15) and abscesses (HR 7.66, 95% CI 2.36–24.9) than children aged <5 years. Of note, the 
study did not stratify risk by disease location, and therefore the frequency of isolated colonic 
involvement, which is higher in younger children, was not controlled for.
35
 In the RISK study (a 
large, North American, prospective inception cohort study of 913 children with CD without 
complicated disease at presentation), which controlled for disease location, the average age at 
diagnosis was older in children with CD who progressed to penetrating disease (aHR 1.45, 95% 
CI 1.17–1.80).
36
 However, other smaller studies did not describe any association between age at 
diagnosis and penetrating disease
10, 24
 and did not find that age at diagnosis independently 
predicts,
24, 36
 or is significantly associated with, progression to stricturing disease, although the 
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mean age at diagnosis was older in those who progressed to stricturing disease (HR 2.15, 95% 
CI 0.99–4.69).
35
 
Four studies examined age as a predictor of progression to the combined outcome of B2 or 
B3 complications; none found age to be significant.
37-40
 
Additional evidence published since the consensus meeting was consistent with previous 
studies. In a Swiss IBD study comparing the risk of complications among adults and children 
with CD, the overall prevalence of strictures, as well as ileal and colonic stricture rates and 
abdominal penetrating disease, were comparable across all age groups; however, rectal, anal, 
duodenojejunal, and multiple strictures were more common in the youngest patients.41 The 
same study found no association between age and long-term disease behavior or complications 
among patients <15 years treated with systemic steroids and immunomodulators.42 
 
Statement 2.2. CD patients of Black ethnicity/race are more likely than White patients to 
develop penetrating (B3) disease (82% agreement). 
In the RISK study, African American children were at higher risk of developing penetrating 
disease (aHR 3.19, 95% CI 1.39–7.31).
36
 Similar results were reported by Eidelwein et al., where 
a higher proportion of Black children progressed to stricturing or penetrating disease than 
White children (29% of Black children vs 11% of White children, P=.05).
30
 A significantly greater 
cumulative incidence of fistula development at 1 year was found in South Asian children (15.4%, 
95% CI 4.1–48.8%) than in White children (4.4%, 95% CI 1.7–11.4%, P=.02).
43
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Statement 2.3. CD patients with small bowel disease (ie, L1 or L3 +/– L4b) have an increased 
risk of developing stricturing complications (B2) and may be at an increased risk of developing 
penetrating complications (B3) (85% agreement). 
Evidence for disease location as a predictor for stricturing and/or penetrating disease is not 
consistent. In a retrospective cohort study of 989 children with CD by Gupta et al., isolated 
small bowel disease was associated with higher risk for developing stricturing complications 
(incidence rate 39% in children with isolated small bowel disease; 19% in children with 
combined small bowel and colonic involvement; 11% in children with isolated colonic disease), 
faster progression to complicated disease (log-rank P=.02) in a univariate analysis, and 
combined outcome of B2/B3 complications (incidence rate 58% in children with isolated small 
bowel disease; 43% in children with combined small bowel and colonic involvement; 22% in 
children with isolated colonic disease; log-rank P=.009 in a univariate analysis).
44
 In contrast, 
ileal location of disease was not a risk factor for stricturing disease in the RISK study (aHR 1.60, 
95% CI 0.88–2.91).
36
 In an additional study of 36 children with stricturing CD, disease location 
was not linked to stricture formation.7 
No association between penetrating disease and disease location was identified in the RISK 
study (isolated ileal disease aHR 1.23, 95% CI 0.51–2.95) or the retrospective study by Gupta et 
al. Three studies did not establish a link between disease location and the combined outcome 
of B2/B3 complications.
38-40
 
 
Statement 2.4.1. Antimicrobial serologies predict progression to stricturing (B2) and/or 
internal penetrating (B3) complications: ASCA positivity predicts progression to internal 
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penetrating (B3) complications and may predict progression to stricturing (B2) complications; 
a higher ASCA immunoglobulin (Ig) A titer predicts progression to penetrating (B3) 
complications (94% agreement). 
Antimicrobial serologies as predictors for disease complications have been examined in 
multiple studies.13, 25, 29, 36, 45 ASCA status was not significantly associated with progression to 
stricturing disease (aHR 2.30, 95% CI 1.26–4.20) in the RISK study
36
; however, both ASCA IgA 
(aHR 2.68, 95% CI 1.19–6.04) and ASCA IgG (aHR 2.38, 95% CI 1.09–1.28) status were 
independently associated with progression to penetrating disease. Moreover, ASCA IgA and IgG 
positivity were associated with more rapid progression to B3 complications than negative ASCA 
IgA or IgG (68 vs 2074 days for ASCA IgA, and 58 vs 1225 days for ASCA IgG). The combination of 
ASCA positivity and antineutrophil cytoplasmic antibody (ANCA) negativity was also significantly 
associated with B3 disease (aHR 1.86, 95% CI 1.25–6.52).
36
 Consistent with these results, ASCA 
IgA positivity was independently associated with progression to penetrating disease when 
disease location, age, and medication use were controlled (aHR 2.84, 95% CI 1.20–6.72), and a 
higher titer of ASCA IgA was associated with a higher risk for penetrating disease (12-unit titer 
increase associated with a 20% increase in hazards).
13
 However, in a single-center longitudinal 
study of 61 children, neither ASCA IgA nor IgG was associated with progression to penetrating 
disease.
29
 
 
Statement 2.4.2. Antiflagellin (CBir1) positivity predicts progression to stricturing (B2) and/or 
internal penetrating (B3) complications; OmpC positivity may predict progression to 
stricturing (B2) and/or internal penetrating (B3) complications (94% agreement). 
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CBir1 positivity was independently associated with penetrating complications (aHR 3.01, 95% 
CI 1.31–6.93) and was a predictor for B2 outcomes (aHR 2.30, 95% CI 1.26–4.20) in the RISK 
study.36 In a follow-up longitudinal study of 536 children, CBir1 was significantly associated with 
combined B2/B3 outcomes (aHR 2.5, 95% CI 1.2–5.2, P<.02), although the pilot study did not 
describe any association.25, 45 
 
Statement 2.4.3. Seropositivity for ≥1 microbial serologies predicts progression to stricturing 
(B2) and/or internal penetrating (B3) disease; a higher number of positive serologies and 
higher titers may confer a greater risk (94% agreement). 
In the same longitudinal study including 536 children described above, a greater proportion 
of children positive for ≥1 microbial biomarker progressed to B2/B3 complication than those 
who were negative for all serologies (9% of children positive for ≥1 of ASCA, anti-OmpC, or anti-
CBir1 developed B2 or B3 complications compared with 2.9% of children who were negative for 
all serologies [P=.01]). Additionally, a dose-dependent increase in risk for B2/B3 complications 
was observed, as aHRs progressively increased with rising antibody sum scores (aHR 6 for 
antibody sum score 3 vs 0) and increasing quartile sum scores (aHR 10 for quartile sum score 
group 4 vs 2).25 
 
Statement 2.5. Polymorphisms in the NOD2/CARD15 gene predict ileal disease location and 
may predict stricturing (B2) disease, but location is inadequately controlled for (90% 
agreement). 
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Associations between NOD2/CARD15 and penetrating18, 20, 21, 24, 36, 46 and stricturing 
complications
14-16, 18-21, 24, 36, 46-48
 were examined with inconsistent results. 
NOD2/CARD15 polymorphisms have been described as risk factors for stricturing disease, 
and despite inconsistent results across studies, a significant association was noted in the meta-
analysis (P=.0002). In a study of 186 children, the odds of developing stricturing complications 
in children carrying at least one 3020insC allele were 6.6-fold higher (odds ratio [OR] 6.62, 95% 
CI 2.69–16.84) than children not carrying this variant.14 Similarly, in a study of 171 children, the 
NOD2 genotype and p.1007fs carrier status showed highly significant associations with 
stricturing complications, the odds of developing strictures were 9.8 times higher in children 
carrying at least one allele for p.1007fs (95% CI 4.05–23.85).
15
 However, multiple studies, 
including the RISK study, did not observe any association between NOD2 genotype and 
stricturing disease.
18-20, 24, 36, 46, 47, 49
 
No association between NOD2/CARD15 and the combined outcome of B2/B3 disease was 
found in two studies.
48, 50
 Of note, it is difficult to estimate accurately the relationship between 
NOD2 and B2/B3 complications, as it is confounded by the association between NOD2 and ileal 
disease location. 
Similarly, NOD2 genotype was not associated with penetrating disease in multiple studies.18, 
20, 21, 24, 36, 46
 
 
Statement 2.6. The presence of perianal disease may predict stricturing (B2) and/or internal 
penetrating (B3) complications (89% agreement). 
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Evidence for perianal disease as a risk factor for progression to complicated disease was 
examined in two studies with inconsistent results.
10, 39
 A multivariate analysis demonstrated an 
increased risk of complex fistulas (OR 3.50, 95% CI 1.98–6.20) and decreased risk of entero-
enteral fistulas (OR 0.30, 95% CI 0.15–0.63) in patients with perianal disease in 12,465 in-
patients <20 years of age with IBD from the Kid’s Inpatient Database in 2009.10 However, in a 
study of 215 children with CD with ≥10 years of follow-up, no association between perianal 
disease at diagnosis and progression was identified.39 
 
Statement 2.7. Sex, family history of IBD, disease activity at baseline, granulomas, upper GI 
tract involvement, presence of extraintestinal manifestations, and diagnostic delay do not 
predict disease location, stricturing (B2) and/or internal penetrating (B3) complications (83% 
agreement). 
Sex as a predictor for progression to stricturing or penetrating diseases was examined in 
multiple studies, with most studies not finding any association.
7, 12, 37-40, 51
 
Of note, a retrospective study of 989 children with CD reported that girls were at lower risk 
for developing a fistula than boys (OR 0.71, 95% CI 0.47–1.05, P=.09); furthermore, no 
significant difference in the risk for developing abscesses (P=.87) or strictures (P=.55) was 
found.
51
 In contrast, in a population-based study of young patients with IBD, females were at 
increased risk for developing complex fistula (rectourethral, rectovaginal, or enterovesical) but 
at decreased risk of developing enteroenteral fistulas.
10
 
A family history of IBD was not a predictor of complicated disease in multiple studies, 
including one registry study of 200 patients with childhood-onset CD, a longitudinal study of 
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215 patients with childhood-onset CD with ≥10 years of follow-up, and a study of 36 children 
with stricturing CD. No evidence was found to support any association between family history 
of IBD and B2/B3 outcomes.7, 38, 39 
Disease severity at diagnosis as a predictor for progression to stricturing or penetrating 
disease was examined in multiple studies. In a study of 63 children, endoscopic activity 
(assessed using the Simple Endoscopic Score) was the only factor independently associated 
with a risk of progression to stricturing/penetrating disease (adjusted risk ratio 3.20, 95% CI 
1.04–4.91); clinical disease activity (pediatric CD activity index [PCDAI]) and histopathology 
(Global Histology Activity Score) were not associated with progression to stricturing or 
penetrating disease. Of note, in this study, B2/B3 complications were considered part of a 
composite outcome that included perianal disease and anti-tumor necrosis factor (TNF) use.37 
Clinical activity (PCDAI), biochemical activity (C-reactive protein [CRP]), hemoglobin, and 
albumin were not significantly associated with B2/B3 complications in a retrospective study of 
215 children with ≥10 years of follow-up.
39
 Consistent with these results, PCDAI and CRP were 
not associated with B2/B3 complications in an IBD study (200 with CD) and a study of 36 
children with stricturing CD.
7, 38
 However, conflicting results were reported from a study 
evaluating the impact of the TNF-α 308 G/A promoter SNP in children with IBD, which found 
that higher PCDAI and CRP were significantly associated with stenosing/penetrating 
complications.
40
 
The presence of granulomas was examined in multiple studies and not found to be 
associated with B2/B3 complications.
32-34, 37, 39, 52
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Similarly, three studies examined upper GI involvement and identified an association with 
the combined outcome of B2/B3 complications.
37, 38, 40
 Extraintestinal manifestations
38, 39
 were 
found to be unrelated to disease progression. 
One study examined diagnostic delay and found that it was not related to disease 
progression.39 
 
Statement 2.8. Older age at CD onset may be associated with an increased risk of developing 
perianal disease (97% agreement). 
A significant association between older age at diagnosis and perianal disease development 
was observed in two studies. A retrospective analysis of a prospective observational cohort 
derived from the ImproveCareNow Network, which included 7,076 children with CD, found that 
whereas the overall odds of developing perianal disease did not differ across age groups, older 
age at diagnosis was associated with a greater risk of developing perianal disease among Asian 
children (OR 1.14, P=.01).
53
 Additionally, significantly more children >10 years at CD onset 
developed perianal disease sooner after diagnosis than those who were ≤10 years of age of CD 
onset (HR 1.13, P<.001). This was confirmed in a study of 215 children with >10 years of follow-
up, where older age at diagnosis was associated with perianal disease development (HR 1.19, 
95% CI 1.002–1.42).
39
 Furthermore, Gupta et al. reported a trend toward perianal disease 
development in older children (>5 years vs 0–5 years) (HR 2.24, 95% CI 0.97–5.19, P=.06).
35
 In 
contrast, patients with and without perianal disease did not differ significantly in age in the RISK 
study; however, the study analyzed patients at the time of presentation rather than perianal 
disease development over time.
36
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Statement 2.9. Children and adolescents of Black and South Asian ethnicity with CD are at a 
greater risk of developing perianal disease (92% agreement). 
As discussed earlier, White children were at a significantly lower risk of developing perianal 
disease than non-White (HR 1.28, P<.001), Black children (adjusted OR 2.47, P=.017), or South 
Asian children.
43, 53
 However, further analyses of the RISK study published since the consensus 
meeting did not identify ethnicity as a risk factor for perianal disease; this evidence was based 
on an assessment of relationships between nicotinamide adenine dinucleotide phosphate gene 
mutation and perianal disease.54 
 
Statement 2.10. Bacterial serology and sex may be associated with the development of 
perianal disease; genetics, antineutrophil cytoplasmic antibody (ANCA) positivity, 
anthropometric parameters, disease location, disease behavior, extraintestinal 
manifestations, diagnostic delay, and disease activity do not predict the development of 
perianal disease (86% agreement). 
Bacterial serological markers, including ASCA, ALCA, antimannobioside carbohydrate 
antibodies, and anti-L antibodies, were independently associated with the composite outcome 
of perianal disease and B2/B3 complications.
27
 In the RISK study, although ASCA IgA and IgG, 
CBir1, granulocyte-macrophage colony-stimulating factor, and OmpC positivity were common 
in children with perianal disease at presentation, these serologic markers as predicters for 
perianal disease were not assessed.
36
 No association was observed between ANCA positivity 
and the risk of perianal disease.
36, 55
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Sex as a risk factor for developing perianal disease was investigated in multiple studies. 
Adler et al. observed an increased risk of perianal disease in boys (OR 1.19, 95% CI 1.04–1.36), 
as well as a more rapid occurrence in boys (HR 1.16, 95% CI 1.04–1.30).53 Similarly, in the RISK 
study, children with perianal disease at presentation were more likely to be boys.
36
 However, 
sex was not associated with perianal disease in a study of 989 children with CD51 or in a long-
term study with a 10-year follow-up that included 215 children.
39
 
Genetic predictors for perianal disease have also been investigated. In a single-center study 
that compared genotypes between childhood- and adulthood-onset IBD, DLG5 rs2165047 was 
significantly associated with perianal disease in patients with childhood-onset CD (risk ratio, 
2.4, 95% CI 1.4–4.0, P=.003).
50
 In a study of 108 Korean children with CD, TNFSF15 rs3810936 
was significantly associated with perianal disease (59% of patients with the CT variant had 
perianal disease vs 20% with the TT variant, P=.029).
56
 Other genes have been investigated 
(NOD2/CARD15,14, 15, 19, 21, 22, 47, 48, 50 TNF,57 MDR1,57 TLR4,50 OCTN,50 IRGM,19, 48, 58 ULK148, and 
ATG16L1)
19, 48
 and did not correlate with perianal disease. 
Anthropometric variables have been examined as potential risk factors for perianal disease. 
In a retrospective analysis of a prospective observational study of 7,076 children with CD, BMI, 
weight, height, and height velocity did not predict the development of perianal disease.53 
Similarly, BMI was not associated with perianal disease in a retrospective study of childhood-
onset CD with at least 10 years’ follow-up.
39
 
Disease location,
36, 39, 53
 disease behavior,
39
 extraintestinal presentation,
39
 delay in 
diagnosis,
39
 and disease activity (PCDAI or PGA)
36, 39, 53
 were not associated with perianal 
disease in any identified studies. 
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Statement 2.11. Male sex, younger age at disease onset, and isolated small bowel disease 
may be associated with a greater risk of linear growth impairment (100% agreement). 
Several large studies have identified an association between male sex and impaired growth. 
Gupta et al. reported that girls were at lower risk for growth failure (height-for-age or height 
velocity <5th percentile) (HR 0.28, 95% CI 0.12–0.63), and that the cumulative incidence of 
growth failure was lower in girls (4%) than in boys (13%).51 Two studies of patients with 
childhood-onset CD reported that boys were at significantly higher risk for growth failure, and 
in one IBD study (211 with CD), a trend toward an association between male sex and final adult 
height was noted.
59-61
 
Age at disease onset was investigated as a predictor for linear growth impairment in 
multiple studies with inconsistent results, possibly owing to the variable definition of growth 
failure. In a Swiss IBD study, transient growth impairment (height z-score below –1.64 on more 
than one occasion) was significantly associated with younger age. The risk for transient growth 
failure was almost seven times higher in children aged 2–11.6 years (than those aged 14.6–18 
years) and 5.4 times higher in children aged 11.8–14 years (than those in the older reference 
group). However, no association between age and permanent growth impairment was 
observed.
62
 In a retrospective study of 87 children, growth retardation (height z-score) was 
linked to younger age of onset, and for every extra year after disease onset, the mean height z-
score nadir increased an average of 0.1 SD.
63
 Furthermore, a French registry study of 261 
patients and a study of 537 patients with childhood-onset CD also identified younger age at 
diagnosis as predictive of growth retardation (height, weight, and BMI in both studies).
60, 64
 Of 
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note, age was positively associated with height velocity in a multivariable analysis in a 
retrospective study of 116 children followed up to 15.4 years.
65
 In contrast, multiple studies 
failed to establish any link between age of CD onset and growth failure, including a registry 
study of 989 children with CD.
35, 51, 61, 66
 
An association between small bowel disease and growth impairment was observed across 
multiple studies. In a study of 87 children, absence of ileal disease (P=.02) and presence of 
colonic disease (P=.004) were predictive of absence of growth retardation (height, weight, and 
BMI).
63
 In a retrospective study of 123 patients with childhood-onset CD, children with jejunal 
disease had significantly lower mean height standard deviation scores (SDSs) than those 
without jejunal disease (–0.70 vs –0.15, respectively, P=.034).
59
 In another study of 93 patients 
with childhood-onset CD, ileal location was significantly associated with height retardation at 
disease onset and the lowest z-score during follow-up.
67
 There are, however, a number of 
studies that found no association between disease location and growth outcomes,9, 25, 62, 64, 68 
although some study results might be confounded by the use of steroids and growth failure as a 
composite outcome with progression to complicated CD or surgery.25, 62, 64 
 
Statement 2.12. More active disease (assessed at baseline or over time) predicts linear 
growth impairment (92% agreement). 
Both clinical and biochemical disease activity were assessed as predictors for linear growth 
impairment. In a study of 53 children with IBD stratified by growth impairment (temporary, 
permanent, or no impairment), significantly higher PCDAI scores were noted in patients with 
transient or permanent growth impairment than in those with no impairment (P=.06) in the CD 
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subgroup.66 Similarly, severe disease (≥1 of cumulative hospitalization time >14 days, steroid 
use, second-line therapy use, or immunosuppressive use) was associated with growth failure (z-
score below –2) in multivariable analysis for both height (OR 6.2, 95% CI 2.23–17.06) and 
weight in another study (OR 4.52, 95% CI 1.44–14.24).
67
 
Multiple studies demonstrated an association between higher erythrocyte sedimentation 
rate (ESR) and linear growth impairment,
61, 65, 69
 with another showing a positive association 
between ESR and delay in the age of the pubertal growth spurt.70 However, CRP and albumin 
were not linked to linear growth,
65, 66, 69
 and growth impairment was not related to serum 
interleukin-6 levels.66 In contrast, higher baseline interleukin-6 levels and PCDAI scores at 
baseline were associated with greater increases in fat-free mass over 2 years.
71
 Insulin-like 
growth factor-1 and insulin-like growth factor binding protein 3 levels were not associated with 
transient or permanent growth impairment.
66
 
 
Statement 2.13. Diagnostic delay is a risk factor for linear growth impairment (92% 
agreement). 
The interval between symptom onset and diagnosis was negatively associated with height 
SDS at diagnosis, suggesting that a shorter time to diagnosis is associated with improved height 
at presentation.
59
 A similar trend was observed in a study of 1,456 children with CD, where 
growth failure was observed in 9.4% of children diagnosed within 3 months, 15.7% of children 
diagnosed at 3–6 months, and 22.3% of children diagnosed >6 months after symptom onset 
(P<.001).
72
 Of note, two studies of children with IBD did not find any association between 
diagnostic delay and height outcomes.
61, 73
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Statement 2.14. NOD2/CARD15 polymorphisms may be associated with low weight, and 
extraintestinal manifestations may be associated with linear growth impairment; pubertal 
status at disease onset, family history of IBD, ethnicity, gestational age, upper GI tract 
involvement, oral involvement, granulomas, disease behavior, perianal disease, and 
presenting symptoms do not predict linear growth impairment (94% agreement). 
NOD2/CARD15 as a risk factor for growth impairment was examined in multiple studies 
yielding conflicting results. One study found that a higher proportion of children with ≥1 
NOD2/CARD15 variants were in the lowest weight and height percentiles compared with 
children without a variant (weight 75% vs 20%, OR 3.7, 95% CI 1.8–7.5; height 50% vs 16%, OR 
5.2, 95% CI 1.7–16), although a link with BMI was not found.16 In contrast, NOD2 was 
significantly associated only with underweight (BMI <10th percentile) at 1 year (P=.012), but 
not with growth failure (inappropriate growth velocity for age) at 1 year or short stature (height 
<3rd percentile) at maximum follow-up.
21
 No link was observed between NOD2 mutations and 
growth retardation (z-score < –1) or growth failure (z-score < –2) at onset, or weight or height 
nadir over follow-up.
67
 
Extraintestinal manifestations as a potential predictor for impaired linear growth were 
investigated across three studies. In a registry study of 261 patients with childhood-onset CD, 
extraintestinal manifestations at diagnosis were significantly associated with height at maximal 
follow-up.
60
 In a study of 537 patients with childhood-onset CD, extraintestinal manifestations 
were linked to growth impairment as part of a composite outcome of disabling CD.
64
 In 
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contrast, in a prospective analysis of 295 patients with childhood-onset IBD (211 with CD), 
extraintestinal manifestations were not associated with final adult height.
61
 
Two studies examined CD onset during puberty as a predictor for impaired growth. 
Although height SDSs were significantly lower in children with prepuberty-onset CD than in 
those with CD onset during puberty (P<.05), the difference was not significant after controlling 
for parental height. Furthermore, patients who had used corticosteroids during puberty were 
significantly shorter than patients who had not (P=.005), which holds true when corrected for 
target height (P=.007).
68
 Similarly, in a study of 221 children with CD, prepubertal disease onset 
was associated with more permanent growth impairment, although the significance was lost 
during a multivariable analysis.
62
 
There was no evidence supporting a link between family history of IBD and growth 
impairment in a retrospective cohort study (n=221), a prospective analysis (n=211), and a 
Belgium registry study (n=255) in patients with childhood-onset CD.9, 61, 62 Similarly, there is no 
evidence to support that ethnicity predicts growth impairment, from the results of a 
retrospective cohort study (n=221), a prospective analysis (n=211), and a retrospective medical 
record analysis of an IBD cohort (n=245).
30, 61, 62
 In addition, in the Belgium registry study, no 
significant association between gestational age and BMI and height at follow-up was found.9 No 
association between upper GI involvement and growth outcomes was found across multiple 
studies, including a retrospective study (n=221), a French registry study (n=261), a study of 
children with IBD (n=54), a study of predictors for disabling CD (n=537), a study of genetic 
predictors for growth retardation (n=93), and a prospective study of 45 newly diagnosed 
patients with childhood-onset CD.
60, 62, 64, 66, 67, 74
 A single study that investigated genetic 
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polymorphisms in 65 Korean children with CD found no link between oral involvement and 
impaired growth.
75
 The presence of granulomas was not identified as a predictor for impaired 
growth, as examined in 45 patients with childhood-onset CD who were followed from diagnosis 
to attainment of final height.
34
 
Disease behavior (stricturing and/or penetrating disease) as a predictor for growth 
impairment was examined in three studies. Although two studies, a retrospective cohort study 
in children receiving steroid treatment (n=221) and a Belgium registry study, did not report a 
link,
9, 62
 one French registry study (n=261) found that nonstricturing, nonpenetrating behavior 
at diagnosis was significantly associated with lower weight at maximal follow-up in 
multivariable analysis (–0.98 SDS vs –0.54 SDS for stricturing and –0.59 SDS for penetrating 
disease, P=.02).60 
Perianal disease as a predictor for growth impairment was investigated in two studies. In a 
study of 537 patients with childhood-onset CD with 5-year follow-up, perianal disease was 
significantly associated with impaired growth as a composite outcome with surgery (P=.05).
64
 
However, a prospective registry (ImageKids) analysis with follow-up of over 18 months did not 
find any link between perianal disease and anthropometrics.
76
 
A study of 989 children with CD from the Pediatric IBD Consortium Registry did not observe 
any association between presenting symptoms and growth impairment.
51
 
 
Statement 2.15. Low height, weight, and body mass index predict reduced BMD (98% 
agreement). 
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Bone health, as assessed by BMD, has consistently been linked with nutritional status 
(assessed by weight and/or BMI). In a study of children with IBD (17 with CD), 24% of patients 
with low lumbar areal BMD were underweight compared with 4% of those with normal BMD 
(P=.009).
77
 In another study of children with IBD (58 with CD), BMI was lower in children with 
BMD z-scores < –1 than in those with a normal BMD at diagnosis, although no link was 
observed between change in BMI and BMD in the longitudinal component of the study.
78
 
Additionally, in a study of 27 children with CD, BMD at follow-up correlated with weight at 
follow-up, although significance was lost in multivariable analysis, and BMI was not associated 
with BMD.79 In a study of 18 children with CD weight and BMI, SDSs were independently 
predictive of a better change in BMD SDS (P=.02 for weight SDS, and P=.03 for BMI SDS).
80
 In a 
2-year longitudinal study in 42 children with CD, fat-free mass and bone mineral content were 
correlated.
71
 Additionally, in 85 children with CD, lean mass correlated with BMD in both boys 
and girls.81 Consistent with these findings, a trend toward lower lean mass z-scores in children 
with low lumbar spine areal BMD (P=.05) was noted in a study of 40 children with CD.
77
 
 
Statement 2.16. Higher clinical disease activity (assessed by Pediatric CD Activity Index 
[PCDAI]) at baseline and over time may predict reduced BMD (98% agreement). 
Studies have reported conflicting results regarding disease activity at baseline and over time 
as a predictor of BMD outcomes. 
In a study of 76 patients with CD (aged 5–21 years), lower PCDAI scores at the start of each 
observation interval and greater reductions in PCDAI over each interval were independently 
associated with greater improvements in trabecular BMD z-scores, although PCDAI was not 
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associated with changes in cortical BMD.82 In a study of 18 children with CD treated with 
adalimumab, lower PCDAI at time of adalimumab initiation was independently predictive of an 
improvement in bone mineral apparent density (P=.02).80 Mean PCDAI over the year preceding 
dual-energy X-ray absorptiometry assessment for bone loss was inversely correlated with 
lumbar spine areal BMD (r=–0.62, P<.001); additionally, patients with moderate-to-severe 
activity (PCDAI >30) had significantly lower BMD area z-scores than those in clinical remission 
for the preceding year (P=.03) in a study of 56 children with IBD (35 with CD).83 In a cross-
sectional study of 119 patients with CD (aged 5–25 years), PCDAI at the time of study visit and 
average PCDAI per year correlated with BMD.84 Similarly, in a retrospective study of 85 children 
and 112 adults with CD, PCDAI scores were 5.8 points higher, on average, in patients with low 
BMD (z-score < –1) than in those with normal BMD (P=.03).21 
In contrast, an association between PCDAI (baseline or change over time) and a change in 
bone parameters were not observed in a study of 78 patients with CD (aged 5–18 years at 
diagnosis).
85
 Similarly, in a single study with children with IBD and three cross-sectional studies, 
PCDAI was associated with BMD.78 Furthermore, PCDAI was not found to be associated with 
BMD in three cross-sectional studies.
77, 79, 86
 
 
Statement 2.17. Sex, disease location, disease behavior, extraintestinal manifestations, 
granulomas, and perianal disease do not predict BMD (84% agreement). 
Seven studies failed to find any link between sex and BMD, including a study in 85 patients 
with childhood-onset CD and 117 with adult-onset CD; a long-term study of 224 patients who 
were diagnosed with CD between the ages of 13 and 19; a prospective follow-up study of 47 
Jo
urn
al 
Pr
e-p
roo
f
26 
 
children and adolescents (24 males) with IBD (17 with CD); a cross-sectional study of 40 
patients with IBD; a longitudinal study of 27 children with CD (20 boys, 7 girls); a cross-sectional 
study of 119 patients aged 5–25 years with CD; and a study of children with IBD (82 with CD).21, 
51, 77, 79, 84, 87, 88
 However, in a prospective study of 76 patients (aged 5–21 years) with CD, 
whereas girls experienced smaller increases in periosteal and cortical area z-scores, sex was not 
related to change in trabecular or cortical BMD z-scores.
82
 In contrast, in a longitudinal cohort 
study of 144 children and adolescents with IBD (45 with CD), boys experienced a more 
pronounced increase in BMD.
89
 
A possible association between disease location and BMD was examined in three studies; 
none of which described a significant association, including a study of 85 patients with 
childhood-onset CD and 117 with adult-onset CD; a study of children with IBD (58 with CD); and 
a longitudinal study of 27 children with CD.
21, 78, 79
 
Associations between BMD outcomes and disease behavior or extraintestinal 
manifestations were not identified in a study comparing adult-onset and childhood-onset CD.
21
 
In addition, a cross-sectional study of 119 patients with CD (aged 5–25 years) did not report any 
association between BMD outcomes and extraintestinal manifestations,
84
 a longitudinal study 
of 27 children with CD found no association between the presence of granulomas and BMD 
outcomes,
79
 and perianal involvement was not a predictive factor in a study of 119 CD patients 
(aged 5–25 years).
84
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Statement 3.1. ASCA positivity may predict the need for more intensive therapy (89% 
agreement). 
Three studies examined ASCA status as a predictor of the need for more intensive therapy 
in children with CD and reported inconsistent results.
7, 28, 90
 Double positivity for ASCA predicted 
an aggressive disease course in Crohn’s colitis (P=.024) and, marginally, the need for biologics 
(10/16 vs 5/17, P=.056).
28
 In 37 CD patients, need for anti-TNF treatment was significantly 
associated with ASCA positivity.90 The third study included only patients with stricturing disease 
(n=36) and found ASCA status not to be associated with partial or complete response to 
therapy (defined as disease behavior B1).7 
 
Statement 3.2. Microscopic ileocolonic involvement at diagnosis may be associated with 
subsequent macroscopic ileocolonic disease (98% agreement). 
In a long-term study of 212 patients with childhood-onset IBD (105 with CD), microscopic 
ileocolonic involvement at diagnosis was more frequent in patients with disease extent 
progression, which was defined as progression from L1, L2, or L4 to L3. Additionally, 
microscopic ileocolonic involvement was an independent predictor for macroscopic ileocolonic 
disease extension (HR 4.32, 95% CI 1.93–9.67, P<.001).39 
 
Statement 3.3. Disease activity and disease behavior (ie, B2 and/or B3), but not age and sex, 
may predict more intensive therapies or a poor response to therapies; there is no strong 
evidence for a predictive value of ethnicity (83% agreement). 
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Three studies examined the correlation between PCDAI at diagnosis and the need for 
second-line therapy. Müller et al. reported a significant association between PCDAI at diagnosis 
and the need for an immunomodulator after 1 year of follow-up in a study of 270 children 
(P=.026).
91
 The other two studies (n=57 and n=37 children with CD) did not find any correlation 
between PCDAI and second-line therapy.92, 93 
Age as a predictor for more intensive therapy or a poor response to therapy was examined 
in 10 studies. Three retrospective studies reported that age at diagnosis was not significantly 
associated with the need for steroids or immunomodulators, or a partial or complete response 
to therapy.7, 94, 95 Additionally, several IBD studies (three studies with 26, 93, and 993 children 
with CD, and two studies with 96 and 160 children with IBD) did not find any association 
between age at diagnosis and subsequent intensive therapy (including corticosteroids, 
immunomodulators, and biologics).
8, 93, 96-98
 Conversely, two studies reported an association, 
including a prospective observational registry study at multiple centers in North America that 
included 1,928 children with IBD, which found that a greater proportion of children aged 1–5 
years with CD (42.9%) were receiving corticosteroids and methotrexate than children older 
than 5 years.
99
 The second study of 506 children found that a significantly greater proportion of 
younger patients (0–5 years) were receiving steroids at the latest follow-up than children older 
than 5 years (P<.05), with no significant difference noted for immunomodulators or biologics.
4
 
Sex also was not a predictor for intensive therapy in four studies.
94, 96-98
 Although one of the 
studies reported a significant association between male sex and a better response to steroids 
30 days after initiation of treatment (n=87, OR 3.2, 95% CI 1.2–8.1), this was not maintained 
over time (n=82, OR 2.5, 95% CI 0.8–7.5).
94
 Of the studies that failed to report any significant 
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findings, two involved large cohorts with >900 children with CD,35, 96 and two included ≤100 
children with a mixed population.
97, 98
 
Two studies identified an association between ethnicity and the need for intensive therapy 
in IBD, but no sub-analyses of children with CD were conducted. One study reported a higher 
need for corticosteroids and infliximab in Black children and a higher need for azathioprine 
during the first 3 months in White children (n=245).
30
 Another study reported that the use of 
methotrexate, steroids, or adalimumab was significantly higher in South Asian children than in 
White children.
43
 
 
Statement 3.4. No strong evidence exists to identify predictive factors of future disease 
activity or disease severity (81% agreement). 
Three studies investigated predictive factors of future disease severity in children with CD, 
two of which identified a link.9, 55, 63 A multicenter study with 155 CD patients and a median 
follow-up of 2.7 years identified L1 (P=.042) and L3 disease (P=.033) at diagnosis as significantly 
related to disease severity at inclusion in a univariate analysis; however, in a subsequent 
multiple regression analysis, only CRP was an independent predictor of disease activity.
9
 The 
second study found that, in childhood-onset CD (n=87), the TNF polymorphism 857C/T was 
associated with a significantly lower risk for severe disease (>2 weeks of hospitalization, >4 
weeks of use of steroids and infliximab, or surgery) (OR 0.32, 95% CI 0.18‒0.56, P=.02), whereas 
TNF 308G/A was associated with a trend toward more severe disease (OR 3.2, 95% CI 1.4‒7.2, 
P=.08).
63
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Although an association between autophagy-associated genes (ATG16L1, IRGM, ULK1, and 
NOD2) and disease behavior was possible, as they were identified using 12 SNPs in a study of 65 
Korean CD patients with a mean follow-up of 4.73 years (±4.4 SDs), the study did not describe a 
significant association between disease behavior and any of the genes.
48
 Similarly, a study of 
102 children with IBD (64 with CD) failed to identify serum ANCA as a significant predictor for 
disease course (quiescent, mild, or severe) in children with CD.
55
 
 
Statement 3.5. No strong evidence exists for predictors of disease relapse and the number of 
relapses (98% agreement). 
Among six studies, there was no strong evidence to support any factors as predictors for 
relapse as the studies were limited by population size and retrospective study design.8, 19, 29, 74, 75, 
100
 
ASCA IgA positivity was significantly associated with relapse in a study of 61 children (OR 2.9, 
95% CI 1.33‒6.35).
29
 In a study of 160 children with IBD (72 with CD), a significantly higher 
incidence of relapse per patient per year was noted in children diagnosed at 5–10 years than in 
children diagnosed at 11–16 years (mean 1.4 ± 0.2 vs 0.85 ± 0.1, P=.05, OR 1.2, 95% CI 1.01–
1.65).8 In a retrospective study of 80 children with CD, a significant association between 
homozygosity of the ATG16L1 risk allele and relapse during the first year of disease (OR 1.2, 
P=.002, multivariate regression analysis) was reported.
19
 In a study of 37 children with CD in 
clinical remission receiving maintenance therapy, there was a significantly increased risk for 
relapse after 1-year follow-up in children with a polymorphonuclear neutrophil CD64 index >1.0 
compared with <1.0 (relapse rate 44% and 5%, respectively, P<.01).
100
 Another study reported 
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that a growth delay at diagnosis was more frequent in children with a relapse; however, the 
study lends little support for growth delay as a predictor owing to the lack of a statistical 
comparison.101 The presence of oral lesions and upper GI tract involvement at diagnosis were 
not associated with number of relapses.
74, 101
 
Conversely, the rate of remission (PGA=0) was significantly higher in IBD unidentified than 
in CD at a median follow-up of 2.8 years (interquartile range 1.6–4.2 years) that included 250 
children with CD, 287 children with ulcerative colitis, and 160 children with IBD unidentified.102 
 
Statement 3.6. Stricturing and/or internal penetrating (B2/B3) phenotype and the presence 
of granulomas and increased visceral adipose tissue may predict hospitalizations; small bowel 
involvement, TNF polymorphisms, NOD2 variants, and age do not predict hospitalization (88% 
agreement). 
Predictors for hospitalization were investigated in seven studies; however, as they were 
mostly single-center studies, the factors identified are not reliable predictors for hospitalization. 
In a single-center study of 289 patients with childhood-onset CD with a median follow-up of 8.5 
years (interquartile range 5.2–11.7 years), the presence of granulomas was associated with an 
increased risk for hospitalization (HR 1.43, 95% CI 1.0–2.0).33 Another single-center 
retrospective study of 114 children with CD reported that an increase in visceral adipose tissue 
significantly increased risk of hospitalization (OR 1.9, 95% CI 1.2–3.4, P=.01), possibly owing to 
association with increased systemic inflammation.
103
 In a retrospective single-center study, no 
significant difference in the incidence of hospitalization was noted in children with (18 out of 23 
children) or without (21 out of 36 children) proximal small bowel involvement.
104
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In a study of 87 children with CD with ≥1 year of follow-up, the presence of TNF 
polymorphisms did not significantly affect the duration of hospitalization.
63
 In a study of 85 
children with CD with ≥2 years of follow-up, NOD2 variants were not predictive of more than 2 
weeks’ hospitalization per year.
21
 
Two studies have reported that age is unlikely to be associated with an increased risk for 
hospitalization, although both studies were conducted in children with IBD. In a prospective 
multicenter observational study of 1,928 children, no difference was observed in the risk for 
hospitalization at baseline, 1-year follow-up, or 5-year follow-up between three subgroups of 
children categorized by age at diagnosis (0–5 years, 6–10 years, 11–16 years).99 The second 
study reported no significant difference in risk of hospitalization (estimated number of 
unplanned inpatient and outpatient days) between children diagnosed at 5–10 years and those 
diagnosed at 11–16 years.
8
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Table 1S. Characteristics of Studies Examining Predictor-Outcome Combinations Not Included in Meta-Analysis 
Study Study design Population 
IBD type 
Age, sex  
Predictors examined (definition, exposed vs 
unexposed) 
Outcomes examined (definition) Follow-up 
duration 
Adler (2017) Prospective,
1
 multicenter 6679 pediatric CD 
Median 12.4 (IQR 9.9–14.8) y, 
59% M 
Weight, height, BMI and height velocity z-score, 
sPCDAI, PGA 
Sex, age, race/ethnicity, geographic regions 
Disease location (lower and upper) 
Perianal disease Median 1.3 (IQR 
0.5–2.6) y 
Alemzadeh 
(2002) 
Retrospective, single 
center (questionnaire) 
135 CD (64 pediatric) 
33% M 
Disease location, age Adult height (SDS, height minus target height) N/A 
Aloi (2014) Prospective, multicenter 506 early-onset IBD 
Mean 10.2 (range 0.8–18.3) y, 
54% M 
Age (0–5 vs 6–11 vs 12–18 y) Surgery (any resection) 
Intensified treatment (on steroids at last follow-up) 
Mean 40 (range 
6–50) mo 
Crocco (2012) Retrospective, single 
center 
45 pediatric CD 
10.9–12.6 y, 58% M 
Upper GIT  PCDAI, number of relapses 
Height and weight percentiles at end of F/U 
Immunosuppressive medication 
Mean 3 (range 2–
4) y 
Cucchiara (2007) 
JPGN 
Retrospective, multicenter 200 pediatric CD 
Mean 12 (SD 4) y, 49% M 
Genetics (TNF variant, MDR1) Surgery (resection), disease behavior, perianal fistulizing 
disease, medication use 
9 (SD 7) y 
De Matos (2008) Retrospective, single 
center 
184 pediatric CD 
Median 12.6 (range 1.06–19.7) y, 
60% M 
Granuloma Perianal disease (deep fissure, fistula, abscess) 
Infliximab, surgery (resection, stricturoplasty) 
B2, B3 
Median 3 (range 
0.4–8.7) y 
De Ridder (2007) Retrospective, single 
center 
103 pediatric CD 
Mean 14 (range 6–18) y, 56% M 
Genetics (NOD2/CARD15 variants, TLR4, OCTN, 
DLG5) 
B2/B3, surgery, perianal disease 
 
N/A 
Dubner (2009) Retrospective, single 
center 
78 pediatric CD 
Mean 12.7 (range 5.5–18) y, 56% 
M 
Tanner stage (1–2 vs 3–5), PCDAI 
Baseline trabecular BMD z-score, muscle CSA z-
score 
BMD (change in trabecular and cortical BMD, change in 
bone strength) 
 
6 mo 
Duchatellier 
(2016) 
Retrospective, single 
center 
221 pediatric CD 
Mean 12.4 (SD 3.2) y, 54% M 
Age (2–11.6, 11.8–14 vs >14.6 y), prepubertal 
status, sex 
Disease behavior, location, upper GIT, disease 
activity 
Family history of IBD, race 
Transient growth impairment (height z-score <5th 
percentile) 
Permanent growth impairment (adult height >8.5 cm less 
than expected) 
Mean 4.9 (SD 2.9) 
y 
Freeman (2004) Prospective, multicenter 
(database) 
224 pediatric CD 
<20 y, 43% M 
Sex 
Disease location, behavior 
B2, B3, surgery (resection) 
Medication use 
Mean 12.2 y 
Freeman (2007) Prospective, multicenter 
(database) 
114 pediatric CD 
<17 y, 46% M 
Granuloma B2 B3 
 
Mean >10 y 
Gasparetto 
(2016) 
Retrospective, multicenter 160 pediatric IBD (mixed IBD 
cohort) 
52% M 
Age (5–10 vs 11–16 y) Surgery, hospitalization 
Intensified treatment (anti-TNF), number of relapses 
Median 1.2–4.2 y 
Guariso (2010) Retrospective, single 
center 
67 pediatric CD (mixed IBD 
cohort) 
Growth deficiency Number of relapses Mean 4.8 years 
Gupta (2004) Retrospective, single 
center 
123 pediatric CD 
Mean 11.8–11.9 (SD 2.4–2.9) y, 
53% M 
Sex BMD (increase/loss spine BMD corresponding to 
highest/lowest quartiles) 
Min 3.4 y 
Gupta (2007) Retrospective, multicenter 989 pediatric CD 
Mean 11.5 (SD 3.8) y, 57% M 
Sex 
Presenting IBD symptoms 
B2, B3 (fistula, abscess), perianal fissure 
Medication use 
Growth failure (height-for-age or height velocity <5th 
percentile) 
Compression fracture or osteopenia/osteoporosis 
Median 2.8 y 
(range 1 d – 16.7 
y) 
Hussey (2011) Retrospective, single 
center 
21 pediatric CD 
Mean 15.7 (SD 1.98) y, 71% M 
Oral manifestations Growth (weight and height z-scores), relapse Mean 55 (SD 22) 
mo 
Ideström (2014) Retrospective, single 45 pediatric CD Granuloma Growth (final adult height SDS adjusted for target height), Median 12.3 
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center Median 10.3 y, 60% M disease behavior, surgery (range 9.3–18) y 
Jakobsen (2011) 
 
Retrospective, single 
center 
105 pediatric CD (mixed IBD 
cohort) 
Median 12.8 (0.4–14.9) y, M 54% 
Age, sex Medication use Median 4.9 (IQR 
3.9–7.6) y 
Jakobstein 
(2006) 
Retrospective, single 
center 
57 pediatric CD patients PCDAI at diagnosis Medication use Min 6 mo 
Laakso (2014) Prospective, single center 17 pediatric CD 
Median 14.5 (range 5.1–19.2) y, 
51% M 
Height-for-age z-score, weight 
(under/over/normal), sex, disease activity 
BMD (lumbar spine areal BMD, height-adjusted whole 
body less head bone mineral content) 
Median 5.4 (4.9–
6.3) y 
Latiano (2009) Retrospective, multicenter 265 pediatric CD 
<19 y, 57% M 
Genetics (IRGM variant) Perianal disease, internal fistulizing disease Mean 8 (SD 7) y 
Ledder (2014) Retrospective, multicenter 47 pediatric CD (mixed IBD 
cohort) 
Age (<6 vs 6–17 y) Medication use Mean 4.5–4.9 y 
Lee (2010) Prospective, multicenter 211 pediatric CD (mixed IBD 
cohort) 
Mean 13.9 (SD 3.9) y, 57% M 
Sex, age, diagnostic delay, EIM, family history of 
IBD, ethnicity 
Parental height, minimum height z-score during 
F/U 
ESR, ethnicity 
Growth (final adult height) Mean 2.3 y 
Lee (2012) Cross-sectional, 
multicenter 
993 pediatric CD 
Median 16.6 (IQR 14.2–18.6) y 
(M), 16.8 (14.4–18.7) (F), 57% M 
Sex, age Growth (BMI z-score, height velocity), medication use Median 16.6 mo 
Lee (2014) Retrospective single 
center 
54 pediatric CD 
Mean 15–16 (SD 2–4) y, 67% M 
Sex, age, SB disease, disease activity (clinical, 
biomarker), upper GIT 
Growth (height-for-age z-score <5th percentile, transient 
or permanent) 
N/A 
Lee (2015) Retrospective, multicenter 108 pediatric CD 
Mean 13 (SD 2.8) y, 69% M 
Genetics (TNFSF15) 
Disease behavior 
Perianal disease, medication use (TNFα) Mean 2.7 (SD 2.2) 
y 
Levine (2005) Retrospective, multicenter 87 pediatric CD 
Mean 12.1 (SD 3.7) y, 63% M 
Genetics (TNF promoter polymorphisms), sex, 
age, disease location 
Growth (weight and height z-score nadir, growth 
retardation – z-score <‒1, failure – z-score <‒2) 
Disease activity/severity (PCDAI, PGA, hospitalization), 
second-line therapy (need for surgery or infliximab) 
Min 1 y 
Lopes (2008) Retrospective, single 
center 
14 pediatric CD (mixed IBD 
cohort) 
Mean 11.8 (SD 4.1) y, 52% M 
Age, height-for-age z-score, BMI z-score BMD (lumbar z-score <‒2) N/A 
Malik (2012) Retrospective, single 
center 
116 pediatric CD 
Mean age 10.8 (range 2.9–15.5) 
y, 59% M 
Age, disease activity (biomarker), weight SDS Growth (height SDS, height velocity SDS) Mean 4.6 
Mason (2011) Retrospective, single 
center 
41 pediatric CD 
Median 12.8 (range 5.3–14.5) y 
(M), 11.6 (8.5–12.8) y (F), 73% M 
Disease activity (biomarker) Growth (peak height velocity SDS, height SDS) Min 2 y 
Mason (2015) Prospective, single center 45 pediatric CD 
Median 13.4 (range 10–16.6) y 
Disease activity (biomarker) Growth (height and height velocity SDS, change in height 
SDS) 
12 mo 
Minar (2014) Retrospective, single 
center 
83 pediatric CD 
Median 15 (range 1–24) y, 61% 
M 
Neutrophil CD64 index Clinical relapse 12 mo 
Mossop (2008) Retrospective, single 
center 
93 pediatric CD (mixed IBD 
cohort) 
Sex, age Medication use (immune modulator) 3.9 (0.5–10.6) y 
Muller 2016 Prospective, multicenter 240 pediatric CD (mixed IBD 
cohort) 
Median 14.2 (11.8–16.1) y, 56% 
M 
PCDAI at diagnosis Medication use (anti-TNFα) 12 mo 
Newby (2008) Retrospective, multicenter 116 pediatric CD (mixed IBD 
cohort) 
Diagnostic delay 
Age, sex 
Growth (height SDS) 
Surgery  
Mean 3.4 y (CD) 
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Median 11.8 (range 4–16) y, 72% 
M 
Olbjorn (2014) Retrospective, multicenter 37 pediatric CD 
Median 13 y, 56% M 
PCDAI at diagnosis 
B3 
Medication use (anti-TNFα) Median 20 (range 
12–24) mo 
Olbjorn (2017) Retrospective, multicenter 37 pediatric CD 
Median 13.9 y, 57% M 
ASCA Medication use (anti-TNFα) Median 20 (range 
12–24) mo 
Oliva-Hemker 
(2015) 
Prospective, multicenter 1928 pediatric IBD, median age 
12.4, 56% M 
Age (1–5 vs 6–10 vs 11–16 y) Medication use 
Hospitalization 
Median 3.25 y 
Olives (1997) Retrospective, multicenter 64 pediatric CD (mixed IBD 
cohort) 
Mean 10.9 (SD 2.1) y (CD), 56% 
M 
ANCA Disease activity (clinical, endoscopic), perianal disease N/A 
Paganelli (2007) Prospective, single center 35 pediatric CD 
Mean 13.5 (range 5–19) y, 63% 
M 
Anthropometrics (height, BMI z-scores) 
Disease activity (PCDAI, biomarker, including 
cytokine levels) 
Bone age, pubertal stage 
BMD (areal BMD, bone mineral apparent density z-score) N/A 
Pichler (2015) Retrospective, single 
center 
18 pediatric CD 
Median 7.8 y (range 2.9–15.3), 
28% M 
Anthropometrics (BMI, weight, height SDS) 
Disease activity (PCDAI) 
BMD (areal BMD, bone mineral apparent density SDS) 1 y 
Rothschild 
(2017) 
Retrospective, single 
center 
289 pediatric CD 
Median 14.2 y, 68% M 
Granulomas Hospitalization, intestinal resection, B2/B3 
 
Median 8.5 y 
Russell (2009) Retrospective 197 pediatric CD 
Median 11.25 (IQR 8.75–13) y, 
58% M 
ASCA Surgery N/A 
Samson (2010) Prospective, single center 27 pediatric CD 
Median 12.5 (IQR 7.2–15.9) y, 
74% M 
Weight, height, growth rate over 1 y SDS, BMI 
percentile 
Disease activity, location 
Age, sex, granulomas 
BMD (change in BMD z-score per chronological and bone 
age) 
1 y 
Sawczenko 
(2006) 
Retrospective, multicenter 123 pediatric CD 
Mean 12.2 (SD 2.8) y, 53% M 
Diagnostic delay, prepubertal status, age, sex, 
disease location, mid-parental height z-scores 
Growth (final height SDS, when growth velocity <1 cm/y x 
at least 6 mo) 
Mean 10.4 (SD 
7.1) y 
Schmidt (2009) Cross-sectional, 
multicenter 
45 pediatric CD 
6–19 y, 65% M 
Anthropometrics (weight, height, BMI) 
Age, sex, disease duration 
BMD (BMD z-score <-2) 2 y 
Schmidt (2012) Cross-sectional, 
multicenter 
37 pediatric CD (mixed IBD 
cohort) 
6–19 y, 64% M 
Sex, age, height (change in z-score) BMD (change) 2 y 
Semeao (1999) Retrospective, single 
center 
119 pediatric CD 
Mean 16.2 (SD 4.1), 61% M 
Anthropometrics (weight, height z-score) 
Sex, age, EIM, perianal disease 
Disease activity/severity (PCDAI, biomarker, 
hospitalization), location 
BMD (z-score <‒1) N/A 
Setty-Shah 
(2016) 
Cross-sectional 15 pediatric CD 
Mean 13.7 (SD 2.6) y, 62% M 
Anthropometrics (weight, height, BMI z-score) 
Disease activity (PCDAI) 
 
BMD (z-score) N/A 
Stordal (2004) Prospective, multicenter 16 CD (mixed IBD cohort) Age Surgery (for B2 complications) 5 y 
Sylvester (2007) Prospective, multicenter 48 pediatric CD 
Mean 13 (SD 3) y 
Anthropometrics (change in BMI, height) 
Disease activity (PCDAI), location  
BMD (change in z-score) 2 y 
Sylvester (2009) Prospective, multicenter 42 pediatric CD 
Mean 12.6 (SD 2.8) y, 69% M 
Nutritional status (fat-free mass) 
Disease activity (PCDAI, biomarker) 
BMD (change bone mineral content) 
Change in fat-free mass z-score 
2 y 
Timmer (2011) Retrospective, multicenter  1,456 pediatric CD 
<18 y, 56% M 
Diagnostic delay Growth failure (as per treating physician) N/A 
Tsampalieros 
(2013) 
Prospective, single center 76 pediatric CD 
Mean 12.6 (SD 2.8) y, 55% M 
Age, sex, disease activity (PCDAI) BMD (change in trabecular, cortical BMD z-score, change 
in cortical area z-score) 
Median 42 (range 
23–54) mo 
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Min 12 mo 
Tung (2006) Retrospective, multicenter 26 pediatric CD (mixed IBD 
cohort) 
15.2 (8.4–18.8) y, 62% M 
Age, sex Medication use 12 mo 
Uko (2014)  Retrospective, single 
center 
101 pediatric CD (mixed IBD 
cohort) 
Median 16 (14–17) y, 55% M 
Visceral adipose tissue Hospitalization  
Surgery 
Min 12 mo 
Vasseur (2010) Retrospective, multicenter 261 pediatric CD 
Median 13 (IQR 11.2–15.4) y, 
60% M 
Age, sex, EIM, upper GIT  Height, weight, BMI Median 73 (IQR 
46–114) mo 
Min 2 y 
Wine (2004) Retrospective, multicenter 93 pediatric CD 
Mean 12.1 (SD 3.6) y, 60% M 
Genetics (NOD2 variant) 
Disease activity, location 
Weight, height failure (z-score <‒2) Min 1 y 
Zwintscher 
(2014) 
Retrospective, multicenter 7846 pediatric CD 
Mean 16 y, 61% M 
Obesity (as per ICD-9 codes) Severe disease, including GI hemorrhage, perforation, 
complex fistulas, surgery 
N/A 
ANCA, antineutrophil cytoplasmic antibodies; ASCA, anti-Saccharomyces cerevisiae antibodies; BMD, bone mineral density; BMI, body mass index; CD, Crohn’s disease; CSA, cross-sectional area; EIM, extraintestinal 
manifestation; ESR, erythrocyte sedimentation rate; F, female; F/U, follow-up; mo, months; GIT, gastrointestinal tract; IBD, inflammatory bowel disease; ICD, International Classification of Diseases; IQR, interquartile range; 
M, male; N/A, not available; PCDAI, pediatric Crohn’s Disease Activity Index; PGA, physician global assessment; SD, standard deviation; sPCDAI, short pediatric Crohn’s Disease Activity Index; SB, small bowel; SDS, standard 
deviation score; TNF, tumor necrosis factor; y, year
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Table 2S. Risk of Bias Studies Examining Predictor-Outcome Combinations Not Included in Meta-Analysis 
Study Representativeness of 
exposed cohort 
Representativeness of non-
exposed cohort 
Ascertainment of 
exposure 
Outcome not 
present at start 
Comparability of cohorts 
(up to 2 stars) 
Outcome 
assessment 
Follow-up long 
enough 
Loss to 
follow-up 
Overall risk of bias 
(number of stars) 
Adler (2017) 1 1 1 1 2 1 1 1 9 
Alemzadeh 
(2002) 
1 1 0 1 0 0 1 1 5 
Aloi (2014) 1 1 1 1 0 1 1 1 7 
Crocco (2012) 1 1 1 1 0 1 1 1 7 
Cucchiara (2007) 1 1 0 0 0 1 1 1 5 
De Matos (2008) 1 1 1 1 0 1 1 1 7 
De Ridder 
(2007) 
1 1 1 0 0 1 0 1 5 
Dubner (2009) 1 1 1 1 2 1 0 1 8 
Duchatellier 
(2016) 
1 1 1 1 2 1 1 0 8 
Freeman (2004) 1 1 1 0 1 1 1 1 7 
Freeman (2007) 0 0 1 0 0 1 1 1 4 
Gasparetto 
(2016) 
1 1 1 1 2 1 1 1 9 
Guariso (2010) 1 1 1 1 0 1 1 0 6 
Gupta (2004) 1 1 1 1 1 1 1 1 8 
Gupta (2007) 1 1 1 0 1 0 1 1 6 
Hussey (2011) 1 1 1 0 0 1 1 0 5 
Idestrom (2014) 1 1 1 0 0 1 1 1 6 
Jakobsen (2011) 1 1 1 1 2 1 1 1 9 
Jakobstein 
(2006) 
1 1 1 1 0 1 0 0 5 
Laakso (2014) 0 0 1 0 1 1 1 1 5 
Latiano (2009) 1 1 1 0 0 0 1 1 5 
Ledder (2014) 1 1 1 1 0 1 1 1 8 
Lee (2010) 0 0 1 0 2 1 1 1 6 
Lee (2012) 1 1 1 0 1 1 0 1 6 
Lee (2014) 1 1 1 0 0 1 0 1 5 
Lee (2015) 1 1 1 0 0 1 1 1 6 
Levine (2005) 1 1 1 1 2 1 0 1 8 
Lopes (2008) 0 0 1 0 0 1 0 1 3 
Malik (2012) 1 1 1 1 0 1 1 1 7 
Mason (2011) 1 1 1 0 0 1 1 1 6 
Mason (2015) 1 1 1 0 0 1 0 1 5 
Minar (2014) 1 1 1 1 1 1 1 1 8 
Mossop (2008) 1 1 1 1 0 1 1 1 8 
Muller (2016) 1 1 1 1 1 1 1 1 8 
Newby (2008) 1 1 1 0 0 1 1 1 6 
Oliva-Hemker 
(2015) 
1 1 1 1 0 1 1 1 7 
Olbjorn (2014) 1 1 1 1 0 1 1 1 7 
Olbjorn (2017) 1 1 1 1 0 1 1 1 7 
Olives (1997) 1 1 1 0 0 1 0 1 5 
Jo
urn
al 
Pr
e-p
roo
f
44 
 
Paganelli (2007) 1 1 1 1 2 1 0 1 8 
Pichler (2015) 0 0 1 1 1 1 1 1 6 
Rothschild 
(2017) 
1 1 1 1 0 1 1 1 7 
Russel (2009) 1 1 1 1 0 1 0 0 5 
Samson (2010) 1 1 1 1 1 1 1 0 7 
Sawczenko 
(2006) 
1 1 1 1 0 1 1 0 6 
Schmidt (2009) 1 1 1 1 1 1 1 0 7 
Schmidt (2012) 1  1 1 1 2 1 1 0 8 
Semeao (1999) 0 1 1 0 2 1 0 1 6 
Setty-Shah 
(2016) 
0 0 1 0 0 1 0 1 2 
Stordal (2004) 0 1 1 1 0 1 1 0 5 
Sylvester (2007) 1 1 1 1 0 1 1 0 6 
Sylvester (2009) 1 1 1 1 0 1 1 0 6 
Timmer (2011) 1 1 0 1 0 0 1 1 5 
Tsampalieros 
(2013) 
0 1 1 1 0 1 1 0 5 
Tung (2006) 1 1 1 1 0 1 1 0 6 
Uko (2014) 1 1 1 1 2 1 1 1 9 
Vasseur (2010) 1 1 1 1 2 1 1 0 8 
Wine (2004) 1 1 1 1 2 1 1 0 8 
Zwintscher 
(2014) 
1 1 1 0 2 1 0 1 7 
Based on Newcastle-Ottawa Scale 
All columns 0 or 1 stars except comparability (0 to 2), last column = total # of stars 
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